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ABSTRACT

Author: Lee, Hyeon Jeong. PhD
Institution: Purdue University
Degree Received: December 2017
Title: Imaging Cholesterol Metabolism and Trafficking by Stimulated Raman Scattering
Microscopy
Major Professor: Ji-Xin Cheng
Cholesterol is an essential component of mammalian cells which is tightly regulated. However,
our understanding of cholesterol transport and metabolism is still incomplete, partly due to lack of
suitable tools for studying cholesterol dynamics in living cells and organisms with spatio-temporal
information. My dissertation work applied spectroscopic imaging of cholesterol in human tissues,
living cells, and model organisms to unravel new insights of cholesterol metabolism and
trafficking.

Using stimulated Raman spectroscopic analysis of lipid droplets in human prostate cancer patient
tissues, we observed an aberrant accumulation of cholesteryl ester in metastatic lesions. Inhibition
of cholesterol esterification in prostate cancer cells significantly suppresses the development and
growth of metastatic cancer lesions in both orthotopic and intra-cardiac injection mouse models.
Gene expression profiling shows that cholesteryl ester depletion suppresses the metastatic potential
through upregulation of multiple regulators that negatively impact metastasis. Additionally,
Wnt/β-catenin, one of vital pathways for metastasis, is downregulated upon cholesteryl ester
depletion. Mechanistically, we found evidence suggesting that inhibition of cholesterol
esterification significantly blocks secretion of Wnt3a through reduction of monounsaturated fatty
acid levels, which limits Wnt3a acylation. These results collectively validate cholesterol
esterification as a novel metabolic target for treating metastatic prostate cancer.

My thesis work also developed a new biocompatible cholesterol analog, which enabled real-time
imaging of cholesterol metabolism and trafficking in living cells and organisms. Based on quantum
chemistry calculations, we designed and synthesized phenyl-diyne cholesterol (PhDY-Chol),
which has an extremely large Raman scattering cross section. The phenyl-diyne group is
biologically inert and provides a Raman scattering cross section that is 88 times larger than the

xv
endogenous C=O stretching mode. Stimulated Raman scattering microscopy offers an imaging
speed that is faster than spontaneous Raman microscopy by three orders of magnitude, and a
detection sensitivity of 31 µM PhDY-Chol (~1,800 molecules in the excitation volume). Inside
living cells, PhDY-Chol mimics the behavior of cholesterol, including membrane incorporation
and esterification. In a cellular model of Niemann-Pick type C disease, PhDY-Chol reflects the
lysosomal accumulation of cholesterol, and shows relocation to lipid droplets after HPβCD
treatment. In living C. elegans, PhDY-Chol mimics cholesterol uptake by intestinal cells and
reflects cholesterol storage. Together, this work demonstrates an enabling platform for study of
cholesterol trafficking in living cells and organisms.
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1. INTRODUCTION

l .l

Intracellular cholesterol trafficking and metabolism

Cholesterol is a lipid with multiple functions. It is an essential component of cellular membrane,
which influences physical properties of membrane such as fluidity [1]. In addition, it plays an
important role in the formation of membrane domains, lipid rafts [1, 2]. Cholesterol serves as the
precursor for steroid hormones (progestogen, corticosteroids, androgens, and estrogens) [3]. Inside
cells, cholesterol modulates various signaling pathways [4, 5], and modifies specific proteins to
control protein trafficking [6, 7]. Therefore, the amount and distribution of cholesterol in a living
cell is tightly regulated [8-10].
1.1.1 Cholesterol synthesis, uptake, and efflux
Mammalian cells have two major sources of cholesterol: de novo synthesis and uptake of lowdensity lipoprotein (LDL). Cholesterol is synthesized through mevalonate pathway [11], which
starts with acetyl CoA. The rate-limiting step in this process is 3-hydroxy-3-methylglutaryl
coenzyme A (HMG-CoA) reductase, which is a membrane protein located in the ER. Exogenous
cholesterol mainly comes from LDL. Cells uptake LDL through LDL receptors via receptormediated endocytosis [12]. Cholesterol is then released from lysosomes to be transported to ER or
plasma membrane [9]. Finally, cholesterol efflux is an essential process occurs either by passive
diffusion or active pathways mediated by ATP-binding cassette (ABC) transporters (e.g. ABCA1,
ABCG1) [13]. High-density lipoprotein (HDL) acts as the major acceptor for cellular cholesterol
efflux, which serves as an important vehicle to transport excess cellular cholesterol to liver for
recycle and excretion [9]. Overall, these processes modulate total cholesterol levels inside cells.
1.1.2 Intracellular cholesterol trafficking
Location of cholesterol is one of major factors that regulate the fate of cholesterol [10]. Therefore,
cholesterol trafficking is tightly controlled [14]. Once cholesterol is synthesized in ER, it leaves
ER rapidly to be transported to plasma membrane through a non-vesicular trafficking process [1517]. Some studies have shown that this process is dependent on caveolin-1 [18, 19]. Other lipidbinding proteins, such as oxysterol binding protein-related proteins (ORPs) [20] and StAR-related
lipid transfer (START) domain containing proteins [21] may also be involved in this process.
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On the other hand, the exogenous cholesterol obtained from LDL uptake goes through endocytic
pathway [12]. After LDL uptake, CE in LDL is hydrolyzed in a hydrolytic compartment [22], after
which moves to the late endosome/lysosome. Then the cholesterol from LDL is exported out of
lysosomes, which is facilitated by Niemann-Pick types C1 (NPC1) and C2 (NPC2) proteins [23].
These cholesterols are transported to plasma membrane or ER [22]. In ER, cholesterol is reesterified and stored in lipid droplets (LDs). ER is also the location where cholesterol modification
of protein occurs [24]. Alternatively, cholesterol in late endosome/lysosome can be transported to
other organelles by Rab9-dependent vesicular trafficking process [9, 10]. Rab9 is a small GTPase,
which plays important roles in vesicular trafficking between late endosomes and the Golgi network
[25].

Steroidogenesis happens in mitochondria. Cholesterol transport to inner mitochondrial membrane
is the rate-limiting step in steroidogenesis [26, 27], which involves steroidogenesis acute
regulatory protein (StAR) and peripheral benzodiazepine receptor (PBR) [28]. StAR contains a
sequence to target the protein to enter mitochondria [29, 30], whereas PBR is outer mitochondrial
membrane protein working as a cholesterol recognition site [31].
1.1.3 Cholesterol homeostasis
Although it is an essential lipid in mammalian cells, excess cholesterol causes cytotoxicity [32].
High level of intracellular free cholesterol has been shown to disrupt membrane fluidity and
membrane domains [33], which lead to loss of function of certain membrane proteins [34] and
altered signaling pathways [32]. Cholesterol crystal is formed when free cholesterol level is very
high, and this needle-shaped structure can disrupt organelles [35]. Some oxysterols generated from
excess cholesterol are harmful to cells [36, 37]. Other mechanism involves apoptotic pathway
induced by free cholesterol overloading [38, 39]. ER stress induced by high level of cholesterol is
also found in various metabolic disorders [40]. Therefore, maintaining cholesterol homeostasis is
critical for cells.

Cholesterol homeostasis is maintained by sensor proteins through a feedback-regulated manner
[41]. There are several different cholesterol sensors on the ER membrane [8]. Scap and HMG CoA
reductase contain sterol-sensing domain (SSD) [42-44], which binds to Insigs protein in the

3
presence of high sterol level. When certain sterols accumulate intracellularly, Insigs binds to HMG
CoA reductase to cause rapid degradation of the enzyme, which suppresses sterol synthesis [44,
45]. Scap mediates translocation of sterol regulatory element-binding proteins (SREBPs), a family
of transcription factors regulating lipid metabolism [46, 47]. SREBPs are ER membrane proteins
in precursor form bound to Scap, and Scap-mediated translocation of SREBPs to Golgi is essential
for cleavage of SREBPs into mature form. Mature SREBPs move into nucleus to upregulate target
genes. When the sterol level elevates, sterol-induced conformation change of Scap causes binding
of Insigs, which prevents Scap from exiting the ER [48]. As a result, SREBPs are retained on the
ER membrane in the inactive form.

There are three isoforms of SREBP, SREBP-1a, SREBP-1c, and SREBP-2 [47], which have
different specificity. SREBP-1c is involved in fatty acid metabolism, SREBP-2 is involved in
cholesterol uptake and synthesis, and SREBP-1a regulates both [49, 50]. Specifically, target genes
of SREBP-1c include ATP citrate lyase, acetyl-CoA carboxylase, and fatty acid synthase, fatty
acid elongase complex, stearoyl-CoA desaturase 1 (SCD1) [51, 52], glycerol-3-phosphate
acyltransferase [47]. SREBP-2 is shown to upregulate LDL receptor, HMG-CoA reductase,
farnesyl diphosphate synthase, and squalene synthase [47]. In addition to the cleavage of SREBP
precursor, SREBPs are also regulated in transcriptional and post-translational levels [53].

Another regulator of cholesterol homeostasis is liver X receptor (LXR). It is a transcription factor
consists of two isoforms, LXRα and LXRβ. While LXRα is expressed mainly in spleen, pituitary,
lung, liver and fat, LXRβ is expressed ubiquitously [54]. LXRs form heterodimers with retinoid X
receptor (RXR) to recruit corepressors and bind to promoters of the target genes [55]. Binding of
oxysterols replaces corepressors with coactivators [56, 57], which promotes expression of genes
involved in fatty acid metabolism, cholesterol efflux and degradation of LDL receptors.
Specifically, its target genes include fatty acid synthase [58], SREBP-1c [59], ABCA1, ABCG1
[60], and Idol [61].

Besides maintaining cholesterol homeostasis through regulation of cholesterol uptake, synthesis,
and efflux, another level of regulation comes from esterification and storage of cholesterol into
LDs [10, 62]. This process is catalyzed by an ER protein known as acyl-coenzyme A: cholesterol
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acyltrasferase (ACAT) [9, 63], with free cholesterol and long-chain fatty acyl coenzyme A as
substrates to generate cholesteryl ester (CE). Although ACAT does not contain SSD, its activity
is regulated through allosteric activation by sterols, preferably cholesterol [64, 65]. By converting
cholesterol into CE, cells can effectively reduce free cholesterol level in the ER membrane,
reducing the cytotoxicity.

Disruption of cholesterol homeostasis is associated with many diseases, including atherosclerosis
[32], metabolic diseases [66], and cancer [67]. Atherosclerosis is caused by building up of plaque
that clog arteries. One of the major risk factors of this disease is increased serum cholesterol [68],
and massive accumulation of CE in macrophage foam cell is a hallmark of early atherosclerotic
lesion [69]. As the lesions become more advanced, free cholesterol content increases at the lesions
[70], indicating the disruption of cholesterol homeostasis during the disease progression. There are
several metabolic diseases that results from defects in genes involved in cholesterol metabolism.
Some of them are caused by alteration in the cholesterol synthesis pathway, such as Smith-LemliOpitz syndrome [71]. In these disorders, intermediate metabolites are accumulated due to defects
in one of enzymes in the cholesterol biosynthesis pathway. Niemann-Pick type C (NP-C) disease
is an autosomal recessive lysosomal storage disorder caused by defects in cholesterol trafficking
[72]. Mutations in NPC1 or NPC2 genes results in accumulation of free cholesterol in late
endosome/lysosome, which cause neurodegeneration [73]. Tangier disease is another disorder
caused by mutations in ABCA1 [74]. In addition to these metabolic diseases, altered cholesterol
metabolism is found in various cancers [67], which is discussed in the next section.

1.2

Cholesterol metabolism in cancer

Cholesterol accumulation in tumor was found as early as in 1900s [75]. Since then, many studies
further show evidence supporting the important roles of cholesterol in cancer development [67].
Based on several epidemiological studies, there is a positive correlation between increased serum
cholesterol and risk for certain types of cancer, such as prostate cancer [76, 77]. The interests in
understanding the functions of cholesterol and utilizing it as a therapeutic target have further
increased when the association between statin, a class of cholesterol synthesis inhibitors, and
reduced cancer risk was observed [78]. However, there are also studies indicating no association
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between cholesterol and cancer progression [79-82]. These controversial results indicate that the
link between cholesterol and cancer is complex.

Despite the controversy from the epidemiological studies, preclinical studies show more consistent
association between high cholesterol and cancer development. For example, cholesterol is shown
to promote formation of more aggressive tumor in the breast cancer mouse model [83].
Furthermore, increased cholesterol synthesis and membrane cholesterol level contribute to
progression of HER2+ breast cancer to more a malignant phenotype [84]. More recently, by
analysis of The Cancer Genome Atlas (TCGA) database [85], alteration in cholesterol pathway in
tumor cells was correlated with cancer patient survival [67]. These studies indicate the important
roles of intracellular cholesterol in cancer cells. Indeed, multiple oncogenic pathways regulate
cholesterol metabolism in cancer. PI3K/Akt pathway enhances cholesterol levels in cancer by
increasing cholesterol synthesis, uptake and suppressing cholesterol export [86, 87]. Activation of
PI3K/Akt pathway also promotes cholesterol esterification, resulting accumulation of CE in LDs
in prostate cancer cells [88]. PKB/Akt promotes cholesterol and fatty acid biosynthesis, which
promotes synthesis of membrane [89]. Spleen tyrosine kinase/PI3K pathway promotes cholesterol
synthesis to maintain the activity of B cell receptor signaling in lipid rafts [89]. Mutant p53 proteins
promotes cancer progression by upregulating mevalonate pathway [90].

Given the essential roles of cholesterol in maintaining cell structure and serving as a precursor for
various signaling molecules, it is hypothesized that increased cholesterol promotes cell
proliferation and survival in various cancer [67]. One mechanism is that increased intracellular
cholesterol level provides membrane components for the formation of lipid rafts [91-93]. In
addition to plasma membrane, cholesterol content in mitochondrial membrane has an important
impact on cancer cell survival. For example, decreased ABCA1 activity in colorectal cancer
promotes cancer cell survival by increasing mitochondrial cholesterol levels [94]. In hepatocellular
carcinoma, mitochondrial cholesterol increases the mitochondrial membrane order, which
contributes to obtaining resistance to chemotherapy [95]. Another mechanism involves regulation
of oncogenic pathways by cholesterol. For example, myristoylated Akt is sensitive to membrane
cholesterol levels, and it requires localization to the cholesterol-rich membrane microdomains to
exert its oncogenic functions [96]. Mevalonate pathway was also shown to regulate Hippo pathway
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to promote proliferation and self-renewal of breast cancer cells [97]. Cholesterol modification of
hedgehog protein [6, 98] is essential for distribution and activity of hedgehog pathway, an essential
pathway that promotes carcinogenesis [99]. Regulation of cell cycle is another important aspect in
cancer cell proliferation. It has been demonstrated that cholesterol is required in the G2-M phase
of cell cycle [100]. In another study, prohibitin was identified as a cholesterol-sensitive cell cycle
regulator which protects prostate cancer from apoptosis [101]. Finally, being a precursor for
steroidogenesis, accumulation of cholesterol in prostate cancer has been proposed to promote
androgen synthesis in tumor which leads to development of castration-resistant prostate cancer
[102-104]. Overall, abnormal cholesterol metabolism plays an important role in cancer
development.

Cholesterol synthesis pathway has been tested for its anti-cancer activities. Statins (HMGCoA
reductase inhibitor), and oxidosqualene cyclase inhibitor reduce tumor growth and metastasis [105,
106]. Blocking exogenous cholesterol source by inhibiting LDL receptor, in combination with
chemotherapy, suppresses pancreatic cancer progression [107]. At the same time, formulation of
anti-cancer drugs into LDL or LDL-like structures shows a potential to enhance drug targeting and
delivery to cancer cells [108]. Suppressing cholesterol storage in cancer cells by inhibiting ACAT
has been shown to suppress tumor growth in prostate [88], pancreatic [109], lung and colon cancers
[110]. More recently, targeting cholesterol transport pathway was proposed suppress cancer cell
survival [111].

In summary, it is becoming clear that deregulation of cholesterol metabolism contributes to cancer
development. Despite the controversial epidemiological studies, preclinical studies demonstrate
important and complex roles of cholesterol in multiple types of cancer. Given the complexity of
cholesterol regulation, deeper understanding of molecular pathways and consequences of aberrant
cholesterol metabolism in cancer is needed to further strengthen the link between cholesterol and
cancer development.

J,3

Conventional analytical tools for tracking cholesterol

There are several different ways to study level, localization and trafficking of cholesterol in cells
or tissues. These techniques utilize reporter molecules which can be divided into two major

7
categories: cholesterol binding molecules and cholesterol analogs [112]. Cholesterol binding
molecules are generally used to quantify the levels of cholesterol or study steady state distribution
of cholesterol. Fluorometric or colorimetric assays based on cholesterol oxidase, sometimes in
combination with cholesterol esterase, are widely used to quantify total cholesterol, free
cholesterol and esterified cholesterol in homogenized samples [113]. However, these assays do
not provide spatial information. Filipin is a commonly used fluorescent cholesterol binding
molecule that can form complex with free cholesterol and visualize distribution of free cholesterol
in fixed cells [114]. Another type of cholesterol binding molecule is perfringolysin O derivatives
[115]. These molecules are shown to have high affinity to free cholesterol and can effectively label
cholesterol-rich domains at the plasma membrane without fixation or in the intracellular structures
with fixation [116].

As cholesterol distribution is an important factor that determines the fate and physiological
functions of cholesterol, visualizing cholesterol and tracking its dynamics are essential.
Unfortunately, cholesterol is a small lipid, which is difficult to label and track in real-time.
Radioactive cholesterol or its precursor is used in biochemical studies aiming to understand
cholesterol trafficking and metabolism [112]. Although this approach provides high sensitivity and
specificity, it has to be used in combination with separation methods to determine intracellular
distribution of cholesterol. Imaging approaches using cholesterol analogs enables real-time
tracking of cholesterol dynamics and provides more accurate spatial information. To image
cholesterol, various fluorescent cholesterol analogs were developed. Dehydroergosterol (DHE) is
an intrinsic fluorescent sterol, which structurally is slightly different from cholesterol. DHE has
been shown to closely mimic the cholesterol physiology [117]. Unfortunately, its fluorescent
property is not optimal due to rapid photo-bleaching and strong overlapping signals from
autofluorescence in tissues or in organisms [112, 118]. Other fluorescent cholesterol analogs
include fluorophore tagged cholesterol molecules such as 7-nitrobenz-2-oxa-1,3-diazole (NBD)cholesterol and boron dipyrromethene difluoride (BODIPY)-cholesterol [119, 120]. These
molecules have more favorable fluorescent properties, but large fluorophore group often interfere
with function of cholesterol [121]. Lastly, clickable cholesterol analogs were developed and used
to study cholesterol-binding proteins [122, 123]. These molecules contain small tag, which
minimize the perturbation, but it requires additional steps before fluorescence imaging.
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As demonstrated in this section, there are many reporter molecules developed to study cholesterol
transportation and metabolism, indicating the importance of understanding cholesterol dynamics
in real-time. At the same time, it is still challenging to study cholesterol in living cells and organism
with the current methods due to the abovementioned difficulties, further stressing the need for
developing new techniques for imaging cholesterol in a living system.

1.4

Stimulated Raman scattering imaging of living cells

The work presented in this section was published in Methods [124]. Reprinted with permission
from [124]. Copyright © 2017 Elsevier Inc.

A central theme of chemical science is deciphering how molecules function in a complex system,
such as a living cell. Such study contributes to the society by providing fundamental knowledge
in medical science to improve our lives. Yet, our understanding of chemistry in living system (e.g.,
how intensive biosynthetic chemical activity drives cell development, function, and inter-cellular
communications) is still limited, partly because conventional biochemical assays treat the cell, a
highly dynamic structure, as a static bag of molecules. In current paradigms, molecules are
extracted from a tissue and analyzed by various analytical techniques such as immunoblotting and
liquid chromatography/mass spectrometry. These in vitro assays provide very little information
about the spatial distribution or temporal dynamics of molecules in real life, thus they are unable
to tell the exact roles of molecular activities on cellular functions [125]. Furthermore, the
molecular profile of a cell may alter during the extensive sample processing procedures. For in
situ imaging, fluorescent microscopy is widely used. By measuring fluorescent signals from
endogenous species, such as coenzymes nicotinamide adenine dinucleotide (NADH) and Flavin
adenine dinucleotide (FAD), cell metabolism can be measured in real time [126-128].
Unfortunately, not all endogenous molecules possess the ideal optical properties. Fluorescent
labels allow imaging of proteins and some key metabolites in living cells, but they often disturb
the function of small biomolecules, such as glucose and cholesterol, limiting the ability to monitor
their activities. These limitations stress the critical need of establishing new platforms for learning
chemistry in situ in living systems.
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Raman-scattering based vibrational spectroscopy has been a powerful tool for non-invasive, labelfree analysis of chemicals. Raman scattering is an inelastic scattering process, in which an
excitation photon loses energy to a certain molecular vibration mode, resulting a scattered photon
with a different wavelength. Such energy losses are directly related to vibrational transitions of a
molecule, showing as peaks in Raman spectrum (Figure 1.1A). Therefore, analysis of Ramanscattered photons can be used to identify chemical species quantitatively. Raman microscope,
which is now commercially available, allows chemical imaging with submicron spatial resolution
[125].

However, because Raman scattering is a feeble process, the image acquisition speed of current
Raman microscopes (at least tens of minutes per frame) is insufficient to follow chemical dynamics
in vivo. To improve the imaging speed, line illumination has been adopted for ultra-fast Raman
imaging, allowing several minutes per frame imaging speed (Nanophoton, Osaka, Japan). To
overcome the speed limitation, coherent Raman scattering (CRS) microscopy [129] has been
developed to enhance the Raman signal level. In CRS microscopy, two excitation beams, known
as pump (ωp) and Stokes (ωs), are used. When the laser-beating frequency (ωp – ωs) is in resonance
with a molecular vibration frequency (Ω), four major CRS processes occur simultaneously, known
as coherent anti-Stokes Raman scattering (CARS), coherent Stokes Raman scattering, stimulated
Raman gain (SRG), and stimulated Raman loss (SRL) (Figure 1.1B). These nonlinear optical
processes offer a large signal that allows live-cell imaging at a speed three to four orders of
magnitude faster than Raman microscope. As nonlinear optical process, CARS and SRS
microscopy offers inherent three-dimensional (3D) sectioning capability. Furthermore, because
CRS microscopy uses near infrared light for excitation, it induces minimal photodamage to cells.

CARS is a four-wave mixing process in which the signal is generated at a higher frequency (Figure
1.1B). CARS signal consists of a non-resonant part independent of the beating frequency and a
resonant part depending on the beating frequency. The non-resonant background part is
contributed by electronic motions [130, 131]. SRG and SRL belong to stimulated Raman scattering
(SRS) [132]. It is a dissipative process accompanied by intensity increase in the Stokes beam and
intensity decrease in the pump beam when the energy difference between the two beams pumps
the molecule from a ground state to a vibrationally excited state (Figure 1.1B). Because SRG and
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SRL signals appear at the same frequency as the incident beams, optical modulation and
demodulation are used to extract those signals. In contrast to CARS, SRS signal is free of nonresonant background, spectral distortion, and is linearly dependent on molecular concentration.
These advantages allow SRS microscopy to study lipids, proteins, nucleic acids, glucose, and other
metabolites in living cells and organisms via quantitative chemical imaging with high sensitivity
[133, 134]. In accordance with the rapid development of SRS microscopy field, there is number
of reviews on application of SRS imaging in living cells and/or biomedical research [135-140]. In
this section, we discuss different SRS imaging modalities and their applications to study chemical
content, transport, and reaction in biological samples.
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Figure 1.1 Spontaneous and coherent Raman scattering processes.
(A) Energy diagram of spontaneous Raman scattering and representative spectra. (B) Energy
diagram of SRS and CARS processes and representative spectra. Broadband coherent
Raman scattering induced by a pump field at ωp and a Stokes field at ωS. Solid arrows
indicates laser excitation and dashed arrow indicates the spontaneous scattering process
Ωvib denotes the vibrational energy.
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1.4.1 SRS imaging modalities
Key components of a SRS microscope include a two-color laser source, an optical modulator, a
laser scanner, a detector and an electronic demodulator (Figure 1.2). Below we will review
recently developed approaches of constructing a SRS microscope.
1.4.1.1 Single-frequency SRS imaging
In single-frequency SRS imaging scheme, the laser energy is focused to a specific Raman mode
of typical bandwidth around 10 – 100 cm-1. To achieve high spectral resolution, picosecond laser
is preferred, especially for imaging narrow Raman bands. At the same time, picosecond excitation
reduces cross-phase modulation background and photodamage. However, SRS is a nonlinear
process, which requires high peak power to generate signals, and the signal level can be increased
by more than one order using femtosecond laser [141]. Moreover, femtosecond excitation is
preferred when the SRS microscope is coupled with other widely used imaging modalities, such
as two-photon excitation fluorescence (TPEF), second harmonic generation, and third harmonic
generation. Several laser sources were developed for SRS imaging: (1) electronically synchronized,
mode-locked Ti:sapphire lasers which produce mode-locked pulse trains with a repetition rate of
~80 MHz and pulse duration from several picoseconds to 100 femtoseconds [142], (2) a modelocked picosecond Nd:YVO4 laser at 1064 nm that synchronously pumps a second beam through
optical parametric oscillator (OPO) [143], (3) a femtosecond Ti:sapphire laser with an OPO [144].

SRS signal appears at the same frequency as one of the excitation beams. To extract the signal,
optical modulation and demodulation are used. Pump or Stokes beam is modulated at megahertz
frequency using acousto-optic modulator (AOM) or electro-optic modulator (EOM). These two
synchronized laser pulses are spatially overlapped and coupled into a laser scanning microscope.
A high numeric aperture objective lens is used for tight focusing. Oil condenser is used to suppress
background from cross-phase modulation by enhancing the signal collection efficiency [145]. A
photodiode is used for the detector, which can withstand high laser power at milliwatt level. SRL
or SRG signal is extracted with a demodulator, such as a lock-in amplifier. As a cost-effective
alternative, a tuned amplifier that resonates at the modulation frequency can also be used as a
demodulator [146]. Various SRS imaging setups have been demonstrated based on the
abovementioned methods.
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Figure 1.2 Instrumentation of SRS microscopy.
Insert: Schematic of the pulse trains in the stimulated Raman loss. OPO, optical parametric
oscillator; AOM, acousto-optic modulator; EOM, electro-optic modulator; CMOS,
complementary metal-oxide-semiconductor.
1.4.1.2 Frame-by-frame hyperspectral SRS imaging
Single-frequency SRS imaging provides real-time chemical imaging based on isolated Raman
bands. However, it is difficult to distinguish spectrally overlapped Raman bands. Hyperspectral
SRS microscopy offers better chemical specificity. Frame-by-frame hyperspectral SRS imaging
records a stack of SRS images at multiple Raman shifts. Wavelength scanning is a straightforward
method for hyperspectral SRS imaging. Using two tunable picosecond lasers, the wavelength is
tuned over a continuous range to cover multiple Raman shifts [147, 148]. The fastest spectral
tuning approach can resolve more than 50 spectrally-distinct frames in ~10 min.

With the broad bandwidth, femtosecond lasers can be used for hyperspectral SRS imaging in
multiple ways. A relatively simple and robust method utilizes spectral focusing technique [149,
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150]. In this approach, two femtosecond laser beams are chirped with NSF57 glass to picosecond
range, which improves spectral resolution [151]. By tuning the time delay between the two chirped
pulses, the frequency difference is subsequently changed to excite different Raman shifts. With
this approach, hyperspectral SRS images can be recorded within a minute over a ~270 cm-1 spectral
window. The important optimization parameters for this method are linear chirping and alignment
of beams and calibration of Raman shift. Another approach uses a pulse shaper to filter and scan
a narrow spectral component out of a broadband femtosecond spectrum [152-154]. Using spectral
filtering coupled with a customized fiber amplifier, a hyperspectral SRS imaging of spectral
resolution better than 10 cm-1 can be reached [155].
1.4.1.3 Multiplex SRS imaging
Hyperspectral SRS imaging generally takes seconds to minutes to obtain the hyperspectral SRS
image stacks. This acquisition speed causes spectral and spatial distortions when imaging dynamic
process happening in vivo. Multiplex SRS microscopy was developed to provides high-speed highcontent biological imaging. Multiple Raman bands can be detected simultaneously in the spectral
domain or in the time domain. The main requirement for multiplex SRS microscopy in spectral
domain is parallel detection of dispersed SRS signals. The detection using a photodiode array has
been demonstrated by Marx et al [156]. To extract the signal, demodulators are required, such as
a high-frequency lock-in amplifier. Lu et al. used three independent lock-in amplifiers to
demonstrate multicolor SRS imaging [157]. A multichannel lock-in amplifier has been developed
for 128-channel multiplex SRS microscopy [158]. Resonant amplifiers[146] provide cost-effective
approach for multiplex detection, and by designing a 32-channel tuned-amplifier array integrated
with a photodiode array, Liao et al. significantly reduced the spectral acquisition time to 32 µs
with a spectral window of ~200 cm-1 [159].

Another approach in time domain utilizes frequency coding. In this approach, each photon is
modulated at certain frequency, which is then collected by a single detector. The spectral
information is extracted by demodulating at different frequencies. Fu et al. [160] demonstrated
parallel detection of three-color SRS imaging by modulating each color of the excitation laser with
an acousto-optical tunable filter at a specific kilohertz-rate frequency. Megahertz-rate modulation
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has been demonstrated by scanning dispersed excitation beam on a spatial pattern inside a
femtosecond pulse shaper, achieving a spectral acquisition within 60 µs per pixel [161].
1.4.1.4 Image analysis
Hyperspectral SRS microscopy generates x-y-Ω image stacks. By extracting spectral profile at
each pixel, concentration maps of different species can be generated. Several imaging processing
methods are available for analyzing hyperspectral SRS image stacks, including principle
component analysis (PCA) [149], multivariate curve resolution (MCR) [152], and spectral phasor
analysis [162]. PCA is used to determine the number of principle components in the hyperspectral
image stack. MCR analysis is a widely-applied method to analyze hyperspectral SRS images [152,
163, 164]. It decomposes the SRS image stack into concentration profiles (matrix C) and spectra
of each component (ST). The dataset D and the reference spectra of each component are entered
in the model D = C · ST + E, in which S contains the output spectra of all fitted components, and
T is the transpose of matrix S. E is the residual matrix or experimental error. Initial estimate of
pure spectra can be obtained from PCA, k-means clustering or prior knowledge of the sample, and
with this information, an alternating least squares algorithm calculates C and S iteratively until
optimal fit to the data matrix D is achieved. The output is a concentration map for every principle
component, expressed as a percentage relative to the intensity of the MCR-optimized spectrum.

1.4.2 Imaging chemistry in cells and tissues by label-free SRS microscopy
Label-free SRS imaging has been applied to in vivo imaging of mouse skin [132, 159-161, 165],
brain [166], Caenorhabditis elegans (C. elegans) [163, 167, 168], Drosophila [169, 170], tadpoles
[171], and human cancer tissues [88, 172, 173]. C-H bond is the most abundant chemical bond in
living cells, providing chemical information of molecules, such as lipids and proteins. Compared
to C-H region where multiple C-H stretching bands are highly crowded and spectrally overlapped,
fingerprint region (500 – 1800 cm-1) is used to provide better chemical specificity for imaging of
nucleic acids, metabolites, and drugs. Below we will review applications of SRS imaging to study
chemical content, dynamics and functions in living cells, tissues, and human samples.
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1.4.2.1 Mapping chemical content in cells and tissues.
Altered lipid metabolism is recognized as a signature of various types of human cancer. Although
intracellular lipid accumulation has been observed in human cancer tissues and cells, it has not
been widely used as a prognostic factor or therapeutic target due to limited understanding of lipid
metabolism in cancer. In particular, the role of lipid accumulation in cancer progression remains
elusive partly because lack of tool for mapping lipid species in a single-cell level. Quantitative
analysis of lipid content at single-cell level in human patient cancerous tissue by coupling confocal
Raman microscopy with SRS microscopy enabled identification of metabolic signature of
aggressive human prostate cancer [88]. The spectroscopic imaging data revealed aberrant
accumulation of CE in LDs of high-grade prostate cancer and metastases, which was shown to be
a consequence of loss of tumor suppressor PTEN and subsequent activation of PI3K/AKT pathway
in prostate cancer cells. Depleting CE storage significantly suppressed tumor growth in mouse
xenograft models and impaired cancer invasion [88]. This work opens opportunities for using
altered cholesterol metabolism for prostate cancer diagnosis and treatment. Recently, by
hyperspectral SRS imaging of single living cells, Li et al. [172] identified lipid unsaturation level
as a metabolic marker for ovarian cancer stem cells. By analysis of ratio between 3002 cm-1 and
2900 cm-1 from the hyperspectral SRS image-stacks, lipid unsaturation levels were mapped in the
individual cells, revealing high unsaturation level in cancer stem cell population. This signature
was shown to be directly regulated by NF-κB and inhibiting lipid desaturation effectively
eliminated cancer stem cells, which blocked tumor initiation capability in vivo [172]. This work
demonstrates the importance of single-cell chemical imaging, which enabled label-free
identification of rare and the most malignant population of cancer cells and cancer stem cellspecific therapy.

At the tissue level, in situ mapping of chemical content allowed visualization of cholesterol crystals,
lipids, proteins, and nucleic acids. By separating sterol C=C band at 1669 cm-1, acyl C=C band
1655 cm-1 and broad amide I band, the distribution of cholesterol crystals, lipids and proteins were
mapped in an intact atherosclerotic arterial tissue [174]. CH2 and CH3 stretching modes represent
major components of lipid and protein, respectively, and are used to map these two compositions
in fresh mouse ear skin [157] and ex vivo mouse skin tissue [160]. Nucleic acid has signature
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Raman peaks at 785 cm-1 and 1090 cm-1, which was used to study the distribution of nucleic acid
in mammalian cells and single salivary gland cells of Drosophila larvae [170].

For medical application, label-free histology by SRS imaging demonstrates one of the important
translational applications of this imaging platform [161, 166, 173, 175]. Histopathology is a
standard examination for diagnosis. However, the current techniques require the tissues to be
frozen or fixed and stained with dyes before they can be observed, which is label-intensive and
time-consuming. By analysis of SRS images at 2850 cm-1 and 2930 cm-1 for CH2 and CH3 vibration
modes, Freudiger et al. [175] showed stain-free histopathological imaging of fresh tissue, which
is comparable to a hematoxylin and eosin (H&E) staining. Using this approach, in vivo SRS
imaging of mouse brain after craniotomy was performed to locate brain tumor margin [166]. More
recently, Lu et al.[173] profiled a range of human brain tumors from patients to establish hallmarks
for glioma classification. Owing to the sharp contrast between lipids and proteins provided by SRS
imaging, vascular proliferation, red blood cells and necrosis were easily discriminated. Moreover,
marked alteration of myelinated fibers observed using SRS imaging of fresh oligodendroglioma
suggested a new mechanism for tumor to modify microenvironment for adaptive advantage [173].
A recent development of spectrometer-free multiplex SRS microscopy further enabled in situ
label-free histological analysis of highly scattered, 5-mm-thick human breast cancer tissues [161].
This work opens opportunities to perform in vivo clinical imaging using label-free SRS
microscopy for cancer diagnosis and tumor margin detection during the surgery.

Chemical mapping in model organisms such as C. elegans has been widely applied to study
metabolic process. Identifying genetic regulators of fat storage has been challenging due to
controversies of the visualization tool for lipids [176, 177] and complication from quantification
of fluorescence labeling and dye-incorporation into lipids in the organisms. Owing to high peak
power, femtosecond excitation was used to increase the SRS signal level and performed label-free
3D sectioning of C. elegans to distinguish fat storage from membrane lipids [141]. SRS imaging
platform has also been combined with RNAi screening to discover novel genetic regulators of fat
storage in C. elegans [168]. Mapping chemical content in C. elegans by hyperspectral SRS
imaging further provided label-free approach to distinguish intracellular compartments, including
fat droplets, lysosome-related organelles, oxidized lipids, and proteins [163]. By examining
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spectral profiles in the fingerprint regions using k-means clustering and MCR analysis, the degree
of lipid unsaturation and oxidation and cholesterol storage were mapped in the entire worm. This
study demonstrates the potential of applying hyperspectral SRS imaging to understand how lipid
storage change in response to diet and the role of insulin in obesity, diabetes and longevity in
animals.
1.4.2.2 Monitoring molecular transport in cells and tissues.
One advantage of label-free imaging is the capability of quantitative long-duration imaging. This
is especially important when studying the dynamics and tracking changes of biomolecules during
ongoing processes, such as embryonic development and injury. Dou et al. [169] performed timelapse SRS imaging of developing Drosophila embryo to track single LD motion within large
populations of droplets. By analysis of velocity and turning frequency of each droplet, the
mathematical model for the LD movement was developed to show key regulatory point of LD
dynamics in the developmental process. [169]. This work shows a potential of using SRS imaging
technique to study lipid trafficking in living cells and organisms. More recently, by in vivo SRS
imaging of single neurons and myelin in the spinal cord, Hu et al. [171] monitored myelin sheath
formation, maturation of a node of Ranvier and myelin degradation in live Xenopus Laevis tadpole.

Dynamic information is especially important in the study of drug molecules in living systems
because the treatment efficiency is highly dependent on the delivery of drug to the target locations.
Several chemical signatures of drug molecules have been used to track drug penetration to skin
and drug release inside living cells. Fu et al. characterized chemical signature of a tyrosine-kinase
inhibitors, which is used for cancer therapy, to image intracellular distribution. The direct
visualization of drug in living cells allowed evaluation of lysosome accusation and release of drug
[150]. Others have demonstrated the tracking of drug molecules penetrating mouse or human skins
using in vivo SRS imaging [132, 165]. By focusing at S=O and C=C bonds, mouse skin uptake of
dimethyl sulfoxide (DMSO) and retinoic acid was imaged. More recently, owing to fast spectral
acquisition speed, multiplex SRS imaging allowed visualization of DMSO drug diffusion through
mouse skin tissues in real-time, revealing fast dynamic diffusion process without spectral
distortion from the motions of the animal [159]. This is not easily achieved using frame-by-frame
hyperspectral SRS imaging. Liao et al. demonstrated in vivo SRS imaging of vitamin E distribution
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on mouse skin by multiplexed modulation at megahertz rate and spectral acquisition within 60 µs
per pixel [161].
1.4.2.3 Probing chemical reaction in cells and tissues.
Metabolic conversion is a dynamic process that happens in living cells and tissues all the time, yet,
the most adopted methods for measuring metabolism is though in vitro analysis of cell or tissue
homogenates. High-speed SRS imaging platform opens the possibility to monitor metabolic
conversions in real-time by probing chemical reactions in situ. By compositional mapping of LDs
in single living cells at the speed of 32 microseconds using multiplex SRS microscopy,
intracellular metabolic conversion of retinoic acids into retinol was monitored in living cells [159].
By developing hyperspectral SRS microscopy with high spectral resolution (9 cm-1) and
submicrometer spatial resolution, aromatic ring of lignin, aldehyde, and alcohol groups in lignified
plant cell walls were spectrally and spatially separated [164]. By analysis of hyperspectral images
with multivariate curve resolution, Liu et al performed real-time monitoring of aldehyde reduction
to alcohol in an intact plant tissue, which represents the lignin reduction. This work demonstrates
the potential of SRS imaging in the understanding of dynamic lignin chemical compositions, which
provides a novel technique for enhancing the efficiency of biomass utilization.
1.4.3 Probing chemical activities in living cells by SRS imaging of Raman probes
Molecules in biological samples contain chemical bonds that are spectrally overlapping. In order
to study the transport or metabolism of a specific molecule, labeling the molecule of interest is
helpful in some cases. Several chemical bonds, such as C-D, C≡C, and C≡N, give Raman signals
in the silent region (1800 – 2800 cm-1), which can be used to label specific molecules to track their
trafficking and metabolism inside living cells and animals. These Raman tags are small, thus can
be used to label small molecules with minimum perturbation of their biological functions, allowing
bio-orthogonal chemical imaging in living cells and organisms.

The introduction of deuterium isotope in biological system has the advantage that it is stable
without radioactivity and replacing hydrogen with deuterium does not change the molecular
structure. Therefore, carbon-deuterium (C-D) bond has been used to label small molecules to study
their uptake and metabolism in living cells and organisms. One example of the application of
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deuterated metabolite is visualizing de novo lipogenesis in living cells by feeding cells with
deuterated glucose [178]. Compared to the currently available glucose analogs, such as 3-Omethylglucose, 2-deoxy-D-glucose and fluoro-deoxyglucose, deuterated glucose can be
metabolized by cells following the metabolic pathways, which allowed tracing of glucose to
lipogenic fate in live cancer cells. De novo protein synthesis is another important process in biology
that is visualized using deuterium labels [179, 180]. Supplemented deuterated amino acids in the
growth medium metabolically incorporate into translational machineries, providing enriched and
specific C-D bond signals for newly synthesized proteins. By comparing with the endogenous
protein Raman peak of Amide I band at 1655 cm-1 or CH3 band at 2940 cm-1, protein synthesis or
degradation can be mapped in living cells [179]. Moreover, Raman peaks of C-D bonds vary
slightly due to the structural differences. Taking advantage of these differences, two-color pulsechase analysis of protein was designed to image formation of protein aggregates. Moving into in
vivo imaging, this technique has been demonstrated in live brain tissues, zebrafish embryos and
mice fed with deuterated amino acids [180]. In addition to glucose and amino acids, choline, a
small molecule for membrane synthesis, neurotransmitter, and signaling pathway, has been imaged
in living cells and C. elegans after metabolic incorporation of deuterated choline [181].

Lipids contain a number of C-H bonds that can be exchanged into C-D bonds, rendering various
lipid species good candidates to be probed with SRS imaging of C-D bonds. Deuterated fatty acids
were used to visualize cellular fatty acid uptake and distribution in LDs and membranes [141]. By
tracing deuterated saturated and unsaturated fatty acids in C. elegans using hyperspectral SRS
imaging, Fu et al. identified different fates of these fatty acids upon uptake in the worms [182].
More recently, deuterated cholesterol was delivered into living cells to visualize cholesterol
storage in steroidogenic cells [183].

As another important application of SRS imaging of C-D bonds in vivo, drug delivery to skin is
studied using deuterated drug applied to animal and human skins. Deuterated DMSO was applied
to human skin, and the penetration into the skin was visualized using epi-SRS imaging [165]. In
another study, anti-inflammatory drug ketoprofen and ibuprofen was imaged in the mouse ear skin
[184]. These studies show the potential of using SRS imaging technique to monitor dermatopharmacokinetics in live animals and humans.
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Although isotope labels provide biocompatible analogs for biological studies, the Raman
scattering cross section of C-D bond vibration is relatively small. Alkyne bond (C≡C) has a Raman
scattering cross section that is larger than most endogenous chemical bonds [185, 186]. The size
of alkyne tag is small compared to a fluorescent dye, making it bio-orthogonal. Direct SRS imaging
of a broad spectrum of alkyne-tagged small molecules, including deoxyribonucleosides,
ribonucleosides, amino acids, choline, fatty acids and glycan, was demonstrated [186, 187]. The
reported SRS detection sensitivity for alkynes is around 200 µM with 100 µs pixel dwell time
[186]. By feeding alkyne-tagged glucose to live tumor xenograft and brain tissues, glucose uptake
was imaged using SRS imaging of alkyne bonds to study glucose uptake patterns [188]. In addition
to biomolecules, alkyne tag has been proven to be an effective approach to image pharmacokinetics
in vivo. Terbinafine hydrochloride, a FDA approved antifungal drug that contains alkyne bonds,
was used to study the delivery of this skin drug to mouse ear tissue to ~ 100 µm depth [186].

Alkyne tag can be modified to further increase SRS signals and reduce cytotoxicity in some cases.
Phenyl-diyne tagged cholesterol was designed to assess cholesterol storage in living cells and in
C. elegans [189]. In this study, distribution of BODIPY-conjugated cholesterol is compared with
phenyl-diyne cholesterol, showing that bulky and lipophilic BODIPY tag bypass metabolic
process of cholesterol and move directly into LDs, whereas bio-orthogonal phenyl-diyne
cholesterol followed cholesterol esterification for storage [189]. It was shown that the Raman cross
section of a phenyl-diyne tag is ~15 times higher than an alkyne tag, achieving the SRS detection
limit of 30 µM phenyl-diyne cholesterol [189]. It should be noted that chirped femtosecond
excitation was used to measure the detection limit of phenyl-diyne bond, whereas picosecond
excitation was used to measure the detection limit of alkyne bond. In this study, probe size and
SRS signal was carefully evaluated to achieve strong signal and biocompatibility, and the tradeoff between these two parameters should be balanced in a case-by-case manner. Collectively, we
expect that development of novel Raman tagged bio-orthogonal molecules will lead to better
understanding of cellular processes by detecting specific chemical activities in situ.
1.4.4 Conclusions and outlook
With the capability of mapping chemical species in living cells and organisms in a label-free
manner, SRS microscopy offers a novel platform to study metabolism, trafficking of organelles,
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and pharmacokinetics in vivo. The integration of SRS microscope and Raman tag provides an
innovative strategy to map the metabolic activities of small molecules in vivo. We note that there
are several limitations and/or disadvantages of current SRS imaging system. Raman scattering
signals of endogenous chemical bonds are sometimes weak, resulting in low detection sensitivity.
Also, the ability to distinguish chemical species may be compromised when there is no
distinguishable vibrational signature due to similarities in chemical bonds. With these
considerations in mind, we expect several promising directions in the future. The first direction is
development of a broadband SRS microscope using an ultrashort pulse laser as excitation source.
By covering the entire fingerprint vibration region, such a system would allow discovery of
signatures inside living cells. The second direction is the study of less abundant metabolites
enabled by further improving the sensitivity. Along this line, we anticipate novel design of Raman
tagged small molecules for dynamic and functional study of biological processes. The third
direction is the development of miniature SRS imaging systems, which have the penitential of
clinical applications, for example, for diagnosis of cancer margin in the operating room.
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2. TARGETING CHOLESTEROL ESTERIFICATION TO SUPPRESS
PROSTATE CANCER METASTASIS

The work presented in this chapter has been submitted to Molecular Cancer Research.

Dysregulation of cholesterol is a common characteristic of human cancers including prostate
cancer. In this study, we observed an aberrant accumulation of CE in metastatic lesions using
stimulated Raman spectroscopic analysis of LDs in human prostate cancer patient tissues.
Inhibition of cholesterol esterification in prostate cancer cells significantly suppresses the
development and growth of metastatic cancer lesions in both orthotopic and intra-cardiac injection
mouse models. Gene expression profiling shows that CE depletion suppresses the metastatic
potential through upregulation of multiple regulators that negatively impact metastasis.
Additionally, Wnt/β-catenin, one of vital pathways for metastasis, is downregulated upon CE
depletion. Mechanistically, we found evidence suggesting that inhibition of cholesterol
esterification significantly blocks secretion of Wnt3a through reduction of monounsaturated fatty
acid levels, which limits Wnt3a acylation. These results collectively validate cholesterol
esterification as a novel metabolic target for treating metastatic prostate cancer.

2. 1

Introduction

Cholesterol is an essential component of mammalian cells and is tightly regulated at multiple levels
[9, 10]. Cells obtain cholesterol from either de novo synthesis or uptake of LDL for construction
of membrane structures [1, 2], steroidogenesis [3], or modulation of protein trafficking and activity
[7]. Cholesterol overloading causes cytotoxicity, and for most cell types, cholesterol efflux is
essential for maintaining its homeostasis [13]. Another mechanism for avoiding free cholesterol
toxicity is by storing excess cholesterol into LDs. This process involves conversion of cholesterol
into CE by ACAT [9, 63]. Cholesterol homeostasis is maintained through a feedback-regulated
manner [8] and disruption of this balance is associated with many diseases such as atherosclerosis
[68], metabolic diseases [66], and cancers [67]. Analysis of TCGA database demonstrates
correlation between cholesterol level and cancer patient survival [67], which supports an important
role of abnormal cholesterol metabolism in cancer development. Other studies on mechanisms
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have also shown the connection between oncogenic pathway and altered cholesterol metabolism
during cancer progression [90, 97].

It was observed several decades ago that cholesterol accumulates in prostate cancer (PCa) [190].
Since then, an increasing number of studies support the indispensable roles of cholesterol in PCa
progression [76, 191, 192]. One hypothesis is that the accumulated cholesterol from either de novo
synthesis or uptake in PCa provides precursor for androgen synthesis within tumor for the
development of castration-resistant PCa [102-104]. Another hypothesis is that increased
cholesterol level supports prostate cancer growth by providing key membrane components such as
lipid rafts [91-93]. Other studies have shown that a certain signaling molecule [96] and cell cycle
regulator [101] are sensitive to intracellular cholesterol level. In the meanwhile, suppression of
cholesterol efflux pathway in advanced PCa was observed [193], which further supports increased
cholesterol level during PCa progression. These extensive studies on functional roles of cholesterol
accumulation in PCa regulated by synthesis, uptake and efflux have provided important insights.
However, our understanding of cholesterol homeostasis in PCa is incomplete, as another critical
aspect of cholesterol metabolism, cholesterol esterification, is relatively understudied. Being an
important buffering mechanism for detoxifying excess free cholesterol [10], esterification of
cholesterol may be necessary for PCa cells to cope with high intracellular cholesterol level.

We previously showed an aberrant accumulation of CE in LDs inside cancerous lesions by
implementing label-free Raman spectroscopic imaging of LDs in human PCa tissues [88]. This
accumulation was found to be a result of loss of tumor suppressor PTEN and subsequent activation
of PI3K/Akt pathway. Increased LDL uptake is the major source of such accumulation. Depleting
CE by ACAT inhibition reduces PCa proliferation and growth in a mouse xenograft model [88].
This study serves as a foundation for developing a therapeutic approach using ACAT as a target.
Nevertheless, it remains unclear what kind of role CE accumulation plays in PCa metastasis and
whether metastasis can be suppressed through CE depletion. Notably, early-stage PCa is often
treated successfully, but late-stage PCa, where cancers have been spread to distant lymph nodes,
bones, or other organs, has a five-year survival rate as low as 29% [194], making metastasis the
major cause of PCa mortality in men. Given that there is currently no effective treatment for this
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disease [195], a deeper understanding into the role of cholesterol esterification in PCa metastasis
would be valuable to the development of novel treatment approaches for metastatic PCa.

In this study, we reveal that CE accumulation is a metabolic signature of human metastatic PCa.
We further demonstrate the suppression of both development and growth of metastatic PCa by
inhibiting cholesterol esterification in an orthotopic mouse model and an intra-cardiac injection
model. Through gene expression profiling, we identified downregulation of Wnt/β-catenin
pathway after CE depletion, confirmed by β-catenin protein levels and distribution in PCa cells.
We further show evidence supporting that CE depletion lowers fatty acid availability for Wnt3a
acylation, which is essential for Wnt-mediated cell migration. These results collectively support
that inhibiting cholesterol esterification suppresses PCa metastasis through impairing Wnt/βcatenin signaling, which opens a new opportunity for treating metastatic PCa.

2.2

Experimental section

2.2.1 Human metastatic PCa tissue specimens and cell lines
The study of human patient specimens was approved by the institutional review board at Purdue
University. Frozen specimens of human metastatic PCa tissues obtained by warm body autopsy
from patients who had failed hormone therapy were obtained from Johns Hopkins Hospital. SRS
imaging and confocal Raman spectroscopy was performed on these tissue slices (~20 µm) without
any processing or labeling.

Cell lines were obtained from American Type Culture Collection (ATCC). PC-3M cell line was
obtained from M.D. Anderson Cancer Center Characterized Cell Line Core. RPMI 1640, F-12K,
non-essential amino acids (NEAA) were purchased from Life Technologies. EMEM was
purchased from ATCC. Fetal bovine serum (FBS) was purchased from Atlanta Biologicals. Cells
were cultured in the following media: PC-3M in RPMI 1640 supplemented with 10% FBS and 0.1
mM NEAA, PC-3 in F-12K supplemented with 10% FBS, LNCaP-HP was derived upon
continuous passage from original LNCaP (ATCC) in RPMI 1640 supplemented with 10% FBS
until the passage number was over 81 following the procedure reported [196-199], DU145 PTEN-
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KD cell line in EMEM supplemented with 10% FBS and 5 µg/mL puromycin (Life technologies).
All cells were cultured at 37˚C in a humidified incubator with 5% CO2 supply.
2.2.2 SRS imaging and quantification of CE in tissues and cell culture
SRS imaging was performed on a femtosecond SRS microscope, with the laser beating frequency
tuned to the C-H stretching vibration band at 2845 cm-1, as described previously [141]. No cell or
tissue damage was observed during the imaging procedure. LD amount was quantified using
ImageJ. Specifically, Threshold function was used to select LDs in the cells due to their
significantly higher signal intensities compared to other cellular structures. “Analyze Particles”
function was then used to quantify the area fractions of LDs in the whole image area, then
normalized to the cell number counted from the same image. Each image contained ~10 cells and
represented as n = 1.

Confocal Raman was performed as described previously [200]. CE percentage in LDs was linearly
correlated with the height ratio of the 702 cm-1 peak (I702) to the 1442 cm-1 peak (I1442) and
expressed as I702/I1442 = 0.00334 × CE percentage (%). CE percentage for each group was obtained
by averaging the CE percentage of LDs in 3 to 6 cells as Raman profiles of LDs in the same
specimen were nearly the same.
2.2.3 Chemicals and reagents
Avasimin was prepared following the protocol described previously [110]. Avasimibe, DMSO,
human albumin, cholesteryl oleate, glyceryl trioleate, myristoleic acid, palmitic acid, palmitoleic
acid, stearate, oleate, linoleic acid, arachidonic acid, and docosahexaenoic acid were purchased
from Sigma-Aldrich. IWP-2 was purchased from Abcam. Recombinant human Wnt3a was
purchased from Bio-Techne Corporation. Luciferin was purchased from Perkin Elmer.
2.2.4 Migration assay
Migration assay was performed in Transwell chambers (Corning) with 8 µm pore-sized
membranes. Cells were pre-treated with indicated treatment for 2 days before transferring to the
Transwell chambers. 2 × 105 cells were seeded in the upper chamber in serum-free media. The
lower chamber was filled with media containing 20% FBS and 50 ng/mL human EGF (Life
Technologies). Cells were then incubated for 20 hr at 37˚C to migrate. The transwell membranes
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were fixed and cells that had not migrated through the chamber were removed with a cotton swab.
Migrated cells were stained with propidium iodide (Life Technologies) and visualized by confocal
fluorescence microscopy. For quantification, average number of cells in 3 fields for one migration
chamber was considered n = 1.
2.2.5 Prostate cancer orthotopic mouse model
Orthotopic model was used to study whether Avasimin treatment can suppress the development of
metastasis in a mouse model. All animal procedures were approved by the Purdue Animal Care
and Use Committee. PC-3M were injected into the prostate of male, 6-week-old NSG mice
(Purdue University Center for Cancer Research) following the protocols reported previously [201,
202]. Specifically, 2 × 105 PC-3M cells were mixed with an equal volume of Matrigel HC (Corning)
and injected into the prostate gland of the mouse. 10 days after the surgery, mice were randomly
assigned into 2 groups for the treatment. Avasimin was dissolved in sterile PBS and administrated
daily via intraperitoneal injections at the dose of 75 mg/kg. The dosage for the treatment was
selected based on previous animal studies [110]. Sterile PBS was used for vehicle group. Primary
tumor volume was assessed twice a week with palpation. Body weight was also measured twice a
week. After treatment for 25 days, tumors and lung were harvested and prepared for tumor volume
measurement, H&E and immunofluorescent chemistry (IFC) staining.
2.2.6 Prostate cancer intra-cardiac injection mouse model
Intra-cardiac injection model was used to study the therapeutic effect of Avasmin to metastasis
already developed in mice by introducing tumor cells directly into the systemic circulation. All
animal procedures were approved by the Purdue Animal Care and Use Committee. PC-3 cells with
stable expression of luciferase (PC-3-Luc) were injected into the heart of male, 7-week-old nude
mice (Envigo) following the protocols reported previously [201]. Specifically, 2 × 105 PC-3-Luc
cells were injected into the left ventricle. 7 days after the injection, mice were randomly assigned
into 2 groups for the treatment. Avasimin was dissolved in sterile PBS and administrated daily via
intraperitoneal injections at the dose of 75 mg/kg. Sterile PBS was used for vehicle group. Tumor
growth was monitored every two weeks by bioluminescent imaging using IVIS in Bindley
Bioscience Center at Purdue. After treatment for 5 weeks, metastatic lesions in the heart, lungs,
pancreas, liver, spleen, intestine, and kidneys were visualized using IVIS. Metastatic lesions were
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harvested and prepared for H&E and spectroscopic imaging. Histological examination was
performed by a pathologist after H&E staining to confirm metastatic lesions.
2.2.7 Histology and IFC staining
Primary prostate tumor and tissues containing metastatic lesions were fixed in 10% neutral
buffered formalin. After paraffin embedding, tissue sections were stained using H&E staining. The
adjacent tissue sections were used for IFC staining. After deparaffinization and rehydration of
tissue slides, antigens were retrieved using unmasking solution (Vector Laboratories) with a 2100Retriever (PickCell Laboratories). Tissue slides were then incubated with anti-human
mitochondria antibody (Millipore MAB1273, 1:100) or anti-Ki-67 antibody (Leica KI67-MM1L-CE, 1:200).
2.2.8 RT-PCR profiler array
Total RNA was extracted from PC-3 treated with DMSO or avasimibe using E.Z.N.A. Total RNA
Kit I (Omega Bio-teck) and reverse transcribed using RT2 First Strand Kit (QIAGEN Inc)
following the manufacturer’s instructions. The human prostate cancer RT2 Profiler PCR Array
(PAHS-135Z) was purchased from QIAGEN Inc and quantitative PCR was conducted following
the manufacturer’s instructions using Roche LightCycler 96. Data analysis was performed based
on the ΔΔCT method with normalization of the raw data to the housekeeping genes using PCR
Array Data Analysis Web portal provided by the manufacturer. To determine fold change in gene
expression, the normalized expression of each gene in the avasimibe-treated sample is divided by
the normalized expression of the same gene in the control sample. Genes were grouped based on
their functions.
2.2.9 Immunoblotting analysis
Cells were lysed in TBSN buffer (20 mM Tris, pH 8.0, 150 mM NaCl, 0.5% Nonidet P-40, 5 mM
EGTA, 1.5 mM EDTA, 0.5 mM Na3VO4, 20 mM p-nitrophenyl phosphate) or RIPA buffer
(Sigma-Aldrich) after indicated treatments. Proteins were detected by immunoblotting with the
antibodies against active β-catenin (Millipore 05-665, 1:1000), β-catenin (Cell Signaling 9562S,
1:2000), Wnt3a (Abcam ab28472, 1:1000), and β-actin (Sigma A5441, 1:5000). The immunoblots
were quantified using Image Lab software (Bio-Rad), using β-actin as a loading control.
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2.2.10 Fatty acid extraction and measurement
PC-3 cells were starved to deplete the fatty acid pool, after which serum is supplemented with
avasimibe (10 µM, 1 days). Free fatty acids were extracted from the cell pellets following the
procedure reported previously [203]. Cell pellets were lysed in 200 µL methanol and acidified with
25 mM HCl. Then the sample was mixed with 1 mL iso-octane, and centrifuged at 3,000 g for 1
min. The top layer was transferred to new vials and the extraction was repeated once with the
bottom layer. The combined iso-octane layers were dried under N2 flow. For quantitative analysis,
each fatty acid at known concentration were used as internal standards. Liquid ChromatographyMass Spectrometry (LC-MS) analysis of fatty acids was performed following the protocol
described previously [204].
2.2.11 Immunoprecipitation of Wnt3a from medium
For immunoprecipitation, 1 mL medium was collected from DU145 PTEN-KD cells and preincubated with 100 µL protein A/G agarose beads (Santa Cruz) on a rotator for overnight at 4˚C.
The beads were discarded and the supernatant was incubated with anti-Wnt3a antibody (2 µg/mL)
on a rotator for 10 – 12 hr at 4˚C and subsequently immunoprecipitated with protein A/G agarose
beads while rotating for 2 hr at 4˚C. The beads were washed once with RPMI buffer supplemented
with protease inhibitor. The proteins were then collected by resuspension in sample buffer and
heated for 10 min at 50˚C. Supernatants were collected and supplemented with 100 mM
dithiothreitol, and the mixture was heated for 5 min at 95˚C before SDS-PAGE.
2.2.12 Statistical Analysis
Results for the animal studies were shown as mean + standard error of the mean (SEM). MannWhitney U-test was used for comparisons between vehicle and Avasimin-treated groups as the
data do not follow normal distribution. Other results were shown as mean + standard deviation
(SD), unless stated otherwise, and Student’s t-test was performed for the comparisons. p < 0.05
was considered statistically significant.
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2.3 Results
2.3.1 CE accumulation in human metastatic PCa tissues
To map the lipid distribution and composition in metastatic PCa, human patient tissues from
multiple metastatic sites, including abdominal soft tissue, liver, adrenal gland, rib and lymph nodes,
were examined by SRS microscopy. C-H-rich lipids were visualized by tuning the laser beating
frequency to be resonant with C-H stretching vibration. LDs were observed in metastatic lesions
of abdominal soft tissue, liver, adrenal gland, rib and lymph nodes (Figure 3.1A). By analyzing
the composition of these LDs with confocal Raman microspectroscopy [200], we found
characteristic bands for cholesterol rings at 702 cm-1 and for ester bond at 1742 cm-1 in the Raman
spectra of these LDs [205] (Figure 3.1B). These spectroscopic signatures indicate the presence of
CE. For quantitative measurement of CE level in these samples, we constructed the calibration
curve for molar percentage of CE in the total lipids based on the Raman spectral measurement of
emulsions containing cholesteryl oleate and glyceryl trioleate. The height ratio between 702 cm -1
cholesterol band and 1442 cm-1 CH2 bending band was linearly proportional to the molar
percentage of CE in the lipid mixture (Figure 3.1C). Based on the calibration curve, we estimated
that LDs in all metastatic lesions are composed of 60 to 80% CE (Figure 3.1D). Our analysis
suggests that accumulation of CE is a metabolic marker for metastatic PCa.
2.3.2 CE depletion suppresses PCa migration in vitro and metastasis in vivo
CE accumulation in metastatic tumor suggests a possible functional role of CE in metastasis. We
hypothesized that depleting CE by ACAT inhibitor would reduce metastatic potential of PCa. To
test this hypothesis, we first examined the migration capability of PC-3M, a metastatic PCa cell
line derived from liver metastasis of PC-3 xenograft [206]. We treated cultured PC-3M with a
potent ACAT inhibitor, avasimibe. To confirm the reduction of CE level after avasimibe treatment,
we measured Raman spectra of LDs in PC-3M cells using confocal Raman microscopy. The
Raman spectral analysis showed a significant reduction in CE level upon avasimibe treatment
(Figure 3.2). To assess migration capability, we performed a transwell assay of PC-3M cells pretreated with avasimibe. Our results indicate that migration capability of PC-3M cells was
suppressed significantly (Figure 3.3). These results suggest that CE depletion impairs the
migration capability of PCa cells.
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Figure 2.1 CE accumulation in human metastatic PCa.
(A) SRS images of metastatic PCa in abdominal soft tissue (ab. soft tissue), liver, adrenal gland,
rib and axillary lymph node (LN). Scale bar: 20 µm. (B) Raman spectra of LDs in
metastatic PCa tissues shown in (A). Spectral intensity was normalized by CH2 bending
at 1442 cm-1. Grey shade indicates the band of cholesterol rings at 702 cm-1. (C)
Calibration curve of molar percentage of CE in total lipid, generated by linear fitting of
height ratio between the peak at 702 cm-1 (I702) and the peak at 1442 cm-1 (I1442). I702/I1442
= 0.00334 × CE %. R2 = 0.99. Error bars represent SD (n = 3). (D) CE molar percentage
in LDs of metastatic PCa in abdominal soft tissue (n = 3), liver (n = 6), adrenal gland (n =
3), rib (n = 3), and axillary lymph node (n = 6). Error bars represent SD.
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Figure 2.2 CE depletion by avasimibe treatment in PCa cells.
(A) An SRS image of PC-3M cells with LDs. Scale bar: 10 µm. (B) Raman spectra of LDs in
PC-3M treated with avasimibe (10 µM, 1 day). Grey shade indicates the bands of
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Figure 2.3 PCa migration suppressed by ACAT inhibition.
(A) Representative images of migration of PC-3M cells pre-treated with avasimibe (10 µM, 2
days). Red: propidium iodide staining. Scale bar: 50 µm. (E) Quantitation of migrated
cells shown in (A). Error bars represent SD (n = 2). **p < 0.005.
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To examine whether CE depletion can suppress PCa tumor metastasis, we generated an orthotopic
mouse model of prostate cancer using the PC-3M cells [201, 202]. The mice bearing an orthotopic
PC-3M xenograft were treated with either vehicle or Avasimin, a systemically injectable
nanoformulation of avasimibe [110]. As illustrated in Figure 3.4A, mice were treated with
Avasimin daily via intraperitoneal injection and tumor metastasis was assessed at the end of the
study by IFC staining of cancer cells in lung tissue sections. Primary prostate tumor growth was
monitored over the treatment period. Avasimin treatment reduced the growth rate of primary
tumors significantly (Figure 3.5A) and inhibited the tumor size by ~1.4-fold at the end of 25-day
treatment (Figure 3.4B). No changes in body weight were observed in mice treated with Avasimin,
indicating no detectable general toxicity to the animals (Figure 3.4C). To characterize primary
prostate cancers after the treatment, we performed IFC staining of prostate tissues harvested at the
end of the study. Anti-human mitochondria antibody was used to specifically label human
cancerous cells presented in mouse tissues (Figure 3.5B). Primary prostate tumors were visualized
in tissues from both vehicle and Avasimin-treated mice. Importantly, we observed that cancer cells
in the vehicle-treated group have invaded into the normal tissues, whereas cancer cells in the
Avasimin-treated group maintained a confined tumor margin (Figure 3.4D). This phenotype was
confirmed by pathological review of the adjacent sections. Furthermore, Ki-67 staining of the
adjacent tissue sections showed lower expression of Ki-67 in Avasimin-treated group compared
to control group, which indicates an anti-proliferating effect of Avasimin to the primary tumor
(Figure 3.4D). Taken together, these results provide evidence that Avasimin treatment suppresses
invasive phenotype and proliferation of primary PCa.
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Figure 2.4 PCa metastasis suppressed by targeting cholesterol esterification in vivo.
(A) Schematic of PCa orthotopic model study. Avasimin (75 mg/kg) was administrated into mice
daily via intraperitoneal injection from 10 days post-transplantation of PC-3M. Vehicle
mice were treated with sterile PBS. (B) Tumor size measured after harvested from
vehicle (n = 7) and avasimin-treated (n = 6) mice. (C) Body weight of the mice over 25day treatments. (D) Representative images of IFC and H&E staining of primary prostate
tumor tissues harvested at the end of the study. Dashed lines indicate clear tumor margins
in the vehicle group. Scale bar: 100 µm. (E) Representative images of IFC staining of
lung tissues harvested at the end of the study with distinct metastatic clusters indicated.
Scale bar: 50 µm. (F) Quantification of metastatic clusters in lung tissues harvested from
vehicle and Avasimin-treated mice. (G-H) Percentage of Ki-67-positive cells in
metastatic tumor lesions harvested from lung tissues of vehicle and Avasimin-treated
mice. Representative images shown in (H). Green: human mitochondria, red: Ki-67, blue:
DAPI. Error bars represent SEM. **p < 0.005.
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Figure 2.5 Primary PCa growth suppressed by targeting cholesterol esterification in vivo.
(A) Primary prostate tumor growth curve estimated by palpation. Error bars represent SEM (n =
7 for vehicle, n = 6 for Avasimin). *p < 0.05. (B) Representative images of IFC staining
of PC-3M xenograft on muscle and lung from a healthy NSG mouse. Dashed line
indicates clear tumor margin. Scale bar: 100 µm.
To assess metastasis in this mouse model, we performed IFC staining of lung tissues with antihuman mitochondria antibody and counted the number of metastatic clusters. Distinct metastasis
was defined by a clear cluster of 5 or more cells [202] (Figure 3.4E, dashed lines), and counted
from the whole lung sections for each mouse. We found a dramatic reduction (~50%) in the
number of metastatic clusters in the lung of Avasimin-treated mice compared to that in vehicletreated mice (Figure 3.4F), indicating reduced metastatic potential of PCa by Avasimin. Moreover,
Ki-67 staining of the adjacent tissue sections showed ~3.5-fold reduction in the level of Ki-67 in
metastatic lesions of Avasimin-treated group, indicating anti-proliferative activity of Avasimin to
the metastatic tumors (Figure 3.4G and H). These results collectively support that CE depletion
by Avasimin suppresses metastatic potential of PCa in vivo.
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2.3.3 CE depletion directly inhibits growth of metastatic PCa in vivo
To determine the clinical potential of CE depletion as a cancer therapy for metastatic PCa, we
examined therapeutic efficacy of Avasimin in an intra-cardiac injection model [201], where
metastatic PCa cells have already spread to other organs at the start of treatment. Seven days after
transplantation of PC-3 cells stably expressing luciferase (PC-3-Luc), the mice were treated with
Avasimin daily via intraperitoneal injection and tumor growth was monitored bi-weekly using in
vivo bioluminescence imaging (Figure 3.6A). A significant reduction of tumor growth rate in
Avasimin-treated group compared to vehicle-treated group was determined (Figure 3.6B and C).
Body weight measurement showed no significant change during the treatment period, indicating
no observable toxicity to the mice (Figure 3.6D). After 35 days of Avasimin treatment, we
observed ~4.7-fold reduction in metastatic tumor size in lungs, liver, and spleen/pancreas (Figure
3.6E and F). To evaluate the amount and composition of LDs in the metastatic cancer, we
conducted spectroscopic analysis on the frozen lung tissue sections. By SRS imaging of the
cancerous lesions, we observed a significant reduction of LDs in Avasimin-treated group
compared to the control group (Figure 3.6G). Confocal Raman spectroscopy further demonstrated
that CE level is significantly reduced in these LDs in Avasimin-treated group (Figure 3.6H),
confirming CE depletion after the treatment. Collectively, these results support our hypothesis that
depleting CE suppresses metastatic tumor growth.

37
A
Inoculation
Week 0

Monitor tumor growth

1

2

3

Euthanize and
collect tissues

Monitor tumor growth
4

5

6

Avasimin daily treatment

Wk 5

Luminescence C
5.0

4.0

3.0
X 106

E

D
1.5

Vehicle
Avasimin

1.0
0.5

30

0 7 14 21 28 35
Day(s) post treatment
Vehicle

--+- Vehicle

-+- Avasimin

25

0.0

0 7 14 21 28 35
Day(s) post treatment

Avasimin

4.0 Luminescence

Heart
& lungs

2.0

Avasimin

35

Body weight (g)

Wk 3

Vehicle

Wk 1

Luminescence (x 108 p/s)

B

3.0

Pancreas

Liver

2.0

Spleen

Intestine

G

H
Vehicle

4.0

2.0

0.0

+

*

Vehicle

Avasimin

1.0 Radiance 2
(p/sec/cm /sr)

Kidneys

Avasimin

CE level (Fold change)

F

Luminescence (x 108 p/s)

1.0
Radiance
(p/sec/cm2/sr)

X 107

1.0

0.5

0.0

**
Vehicle Avasimin

Figure 2.6 Metastatic PCa growth inhibited by CE depletion in vivo.
(A) Schematic of PCa intra-cardiac injection model study. Avasimin (75 mg/kg) was
administrated into mice daily via intraperitoneal injection from 7 days post-inoculation of
PC-3-Luc. Vehicle mice were treated with sterile PBS. (B) Representative IVIS images
of mice treated with vehicle (n = 8) and Avasimin (n = 9). (C) Tumor growth curve
quantified by total intensity of IVIS imaging. (D) Body weight of the mice over 35-day
treatments. (E) Representative IVIS images of metastatic lesions in organs. (F)
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(H) CE level in the metastatic lesions shown in (G). Error bars represent SEM (n > 3).
*p < 0.05, **p < 0.005.
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2.3.4 Gene expression profiling reveals inactivation of Wnt/β-catenin pathway by CE
depletion
To unveil the signaling pathways that are associated with CE accumulation and/or depletion, we
measured the expression levels of 84 human PCa-related genes after inhibiting cholesterol
esterification in PC-3 cells, a metastatic PCa cell line [207]. After confirming CE depletion with
avasimibe using confocal Raman microscopy (Figure 3.7A and B), the gene expression analysis
was performed using a RT-PCR profiler array. The analysis revealed increased expression of
regulators that negatively impact metastasis (DKK3 [208], DLC1 [209], FOXO1 [210], GNRH1)
and genes that are lost in metastatic PCa (EGR3 [211], GPX3 [212], NKX3-1 [213]) (Figure 3.7C
and Figure 3.8A). At the same time, expression level of proliferating marker gene MKI67 was
decreased dramatically, supporting suppressed cancer proliferation by avasimibe (Figure 3.7C and
Figure 3.8B). We also note that CE depletion by avasimibe inhibited expression of ERG by ~2.8fold, which is a common proto-oncogene in PCa (Figure 3.7C and Figure 3.8B). Overall, these
results indicate that CE depletion by avasimibe suppresses proliferation and metastatic potential
of PCa through upregulating multiple negative regulators of metastasis.
Among these metastasis-related genes, DKK3 is a negative regulator of Wnt/β-catenin pathway,
one of the major oncogenic pathways associated with PCa progression and metastasis [214, 215].
To confirm that CE depletion inactivates Wnt/β-catenin, immunoblotting of β-catenin was
performed in PC-3 cells after ACAT inhibition by avasimibe. Protein level of active β-catenin
significantly decreased after avasimibe treatment (Figure 3.7D). To eliminate the possibility of
nonspecific targeting by ACAT inhibitor, we knocked down ACAT-1 using shRNA (Figure 3.9A).
ACAT-1 knockdown in PC-3 depleted CE (Figure 3.9B and C) and resulted in significant
reduction of active β-catenin protein level (Figure 3.7D). Since active β-catenin translocate to
nucleus to act as a transcription factor, we analyzed localization of β-catenin by
immunofluorescence staining. CE depletion by either avasimibe or ACAT-1 knockdown reduced
nuclear localized β-catenin in PC-3 (Figure 3.7E and F, Figure 3.9D and E). To test whether βcatenin inactivation by ACAT inhibition occurs to other aggressive PCa cell lines, we used two
other CE-rich aggressive PCa cell models developed from LNCaP and DU145. LNCaP-HP (high
passage) is a cell line derived upon continuous passage from LNCaP-LP (low passage) until the
passage number exceeds 81 [196], which shows more aggressive and invasive phenotypes
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compared to LNCaP-LP [196-199]. DU145 with stable PTEN knockdown (DU145 PTEN-KD) is
an invasive cell line [216] containing significantly higher CE compared to PTEN wildtype DU145
[88]. In both cell models, CE depletion by avasimibe significantly downregulated β-catenin
(Figure 3.10), which also supports inactivation of Wnt/β-catenin signaling by ACAT inhibition.
These results collectively indicate that CE depletion inactivates Wnt/β-catenin pathway in
aggressive PCa cells.
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Figure 2.7 Depleting CE downregulates Wnt/β-catenin pathway.
(A) SRS images of PC-3 cells treated with avasimibe (5 µM, 3 days). Scale bar: 10 µm. (B) CE
percentage in PC-3 cells shown in (A). Error bars represent SD (n = 10). (C) Expression
profiling of 84 PCa-related genes in PC-3 cells shown in (A). Upregulation is indicated
by shades of red, and downregulation is indicated by shades of green. Grey indicate genes
that are not expressed. ±1.5-fold change is set as a threshold. ECM: extracellular matrix,
GF: growth factor. (D) Immunoblot of antibodies against active β-catenin (dephosphorylated at Ser37 and Thr41) and β-actin in PC-3 cells treated with concentrations
of avasimibe as indicated for 2 days or with ACAT-1 shRNA. (E) Immunofluorescent
staining of β-catenin in PC-3 cells treated with concentrations of avasimibe as indicated
for 2 days. Scale bar: 10 µm. (F) Quantification of cells with nuclear β-catenin after
avasimibe treatment. Error bars represent SD (n > 90 in each group). **p < 0.005, ***p <
0.0005.
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Figure 2.8 Expression profiling of PCa-related genes after ACAT inhibition.
(A) Changes in expression of 7 genes that negatively impact PCa metastasis after ACAT
inhibition in PC-3 cells. (B) Downregulated genes after ACAT inhibition in PC-3 cells.
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Figure 2.9 Inactivation of Wnt/β-catenin pathway by ACAT-1 knockdown.
(A) ACAT-1 expression level in PC-3 cells treated with ACAT-1 shRNA. Error bars represent
SD (n = 2). (B) Raman spectra of LDs in ACAT-1 knocked down PC-3. Grey shade
indicates the bands of cholesterol rings at 702 cm-1. (C) Change in CE molar percentage
in LDs of ACAT-1 knocked down PC-3. Error bars represent SD (n = 8). (D)
Immunofluorescent staining of β-catenin in ACAT-1 knocked down PC-3 cells. Scale
bar: 10 µm. (E) Quantification of cells with nuclear β-catenin after ACAT-1 knockdown.
Error bars represent SD (n > 90 in each group). *p < 0.05, **p < 0.005, ***p < 0.0005.
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Figure 2.10 Inactivation of Wnt/β-catenin pathway by CE depletion.
Immunoblot of antibodies against β-catenin and β-actin in LNCaP-HP and DU145-PTEN
knockdown (DU145 PTEN-KD) treated with concentrations of avasimibe as indicated for
2 days.
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2.3.5 CE depletion suppresses lipogenic potential of PCa
In Wnt/β-catenin signaling pathway, lipid modification of Wnt is a prerequisite for Wnt activation
[217, 218]. During the acylation process, fatty acids serve as substrates for this reaction.
Interestingly, we observed decreased amount of LD in Avasimin-treated metastatic PCa tissues
(Figure 3.6G) and avasimibe-treated PCa cells (Figure 3.7A), suggesting the possibility of
reduced lipogenic potential. Considering the crosstalk between regulation of cholesterol and fatty
acid metabolisms [219, 220], we hypothesized that CE depletion limits availability of fatty acid
substrates for Wnt acylation. To test our hypothesis, we performed SRS imaging on LDs in PCa
cell lines after ACAT inhibition (Figure 3.11A). From analysis of LD amount in SRS images, we
found ~1.7-fold reduction in the number of LDs in cells treated with avasimibe or with ACAT-1
shRNA (Figure 3.11B). To confirm that such reduction is a result of decreased lipogenesis or
uptake, the levels of free fatty acids in PCa were analyzed using LC-MS. Overall, fatty acid
synthesis or uptake in CE-depleted cells was reduced for most of fatty acid species tested, except
for docosahexaenoic acid (C22:6) (Figure 3.11C-E). The most significant reduction was found in
monounsaturated fatty acids (C14:1, C16:1, C18:1) (Figure 3.11D). These results support our
hypothesis that CE depletion reduces free fatty acid availability in PCa.
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Figure 2.11 ACAT inhibition reduces fatty acid levels in PCa.
(A) SRS images of PC-3 and LNCaP-HP cells treated with avasimibe (10 µM, 2 days) or with
ACAT-1 shRNA. Scale bar: 10 µm. (B) Quantitation of LD amount normalized to control
groups. Error bars represent SD (n > 9). (C-E) LC-MS measurement of fatty acids from
lipids extracted from PC-3. Fatty acid levels were normalized by cell number in each
group. Fatty acids are grouped in saturated fatty acids (C), monounsaturated fatty acids
(D), and polyunsaturated fatty acids (E). Error bars represent SEM (n = 3).
*p < 0.05, **p < 0.005, n.s.: not significant.
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2.3.6 CE depletion suppresses cell migration through inhibiting Wnt3a secretion
Stabilization and nuclear transport of β-catenin is a result of Wnt activation, which requires
secretion and binding of lipid-modified Wnt to membrane proteins [217, 218]. As fatty acid levels
in cells decrease, substrates for Wnt acylation become limited. We note that one decreased
monounsaturated fatty acid after ACAT inhibition, palmitoleic acid (C16:1), is the fatty acid
species used for Wnt acylation required for secretion [218]. Therefore, it is likely that Wnt
secretion is inhibited as a consequence of CE depletion. First, we tested whether Wnt is inactivated
after CE depletion by visualizing its location. By immunofluorescent staining of Wnt3a in PCa
cells after avasimibe treatment, we observed membrane localized Wnt3a in control cells (Figure
3.12A), indicating activation of Wnt3a. In contrast, avasimibe-treated cells show dramatic ~6-fold
reduction in membrane-bound Wnt3a, accompanied by intracellular aggregates of Wnt3a (Figure
3.12A and B). The Wnt3a distribution after avasimibe treatment resembles the localization of
Wnt3a after IWP-2 treatment, a potent inhibitor of Wnt3a acylation [221] (Figure 3.12A). To
further confirm inactivation of Wnt3a, we measured intracellular and secreted Wnt3a after
avasimibe treatment using immunoblotting analysis. Intracellular Wnt3a level increased after
avasimibe treatment, while medium Wnt3a level decreased by ~1.4-fold (Figure 3.12C). These
results indicate that avasimibe treatment inactivates Wnt/β-catenin pathway through reducing Wnt
secretion.
To test whether Wnt/β-catenin is an essential pathway that links CE accumulation to
aggressiveness of PCa, we performed a migration rescue experiment with Wnt3a. CE depletion by
avasimibe significantly suppressed migration capability of PCa by ~42% (Figure 3.12D and E).
When Wnt3a was supplemented into the medium, migration capability of the cells was rescued
significantly (Figure 3.12D and E), although not to the full extent (~86% recovery). These results
indicate that CE depletion suppresses PCa aggressiveness largely through Wnt/β-catenin pathway.

Based on our data, we propose that blocking cholesterol esterification creates imbalance in cancer
lipid metabolism that is important for modulating the activities of Wnt/β-catenin pathway (Figure
3.12F). Under normal condition, excess cholesterol in PCa cells is esterified and stored in LDs by
ACAT, and high level of lipid synthesis and/or uptake [222-224] provides sustained, ample supply
of fatty acids (i.e. palmitic acid and palmitoleic acid) for acylation of Wnt protein. Lipid-modified
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Wnt is secreted and bound to membrane to exert its functions, such as promoting cell migration
and invasion. By inhibition of cholesterol esterification, expression and cleavage of SREBP-1
decreased as we reported previously [88]. Consequently, the unavailability of fatty acids inhibited
the Wnt acylation and secretion. Unable to bind to the membrane, the inactivation of Wnt/β-catenin
signaling suppressed PCa migration and metastasis.

2.4

Discussion

Metastatic PCa is a deadly disease still in need of effective treatment [225]. Androgen deprivation
therapy (ADT) is the first-line hormone treatment for metastatic PCa [226]. Despite initial tumor
regression, progression into castration-resistant PCa is inevitable [195]. Although drugs that target
androgen receptor or androgen synthesis (i.e. enzalutamide or abiraterone) show clinical benefits
[227], resistance to these treatments eventually occur [228]. These phenomena show that current
therapeutic strategies for metastatic PCa are still not curative [195] and development of new
treatments is needed to improve patient outcomes.

In this study, we revealed an essential role of CE in metastasis and its potential as a therapeutic
target for metastatic PCa. Using two animal models that focus on different aspects of metastatic
PCa, we tested the therapeutic benefits of CE depletion on development of metastasis and growth
of metastatic tumors in mice. PCa metastasis in an orthotopic mouse model involves escape of
cancer cells from the primary tumor site and migration into other organs. It also provides
information about the therapeutic effect on the primary tumor. Using this mouse model, we
observed striking phenotypic differences between the primary tumors in vehicle versus that in
Avasimin-treated mice, which provides strong evidence that ACAT inhibition suppresses
invasiveness of PCa cells. Consistently, we observed a reduced number of metastatic nodules in
Avasimin-treated mice, supporting that ACAT inhibition suppresses development of metastasis
during PCa progression.
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Figure 2.12 CE depletion inhibits cell migration through reducing Wnt3a secretion.
(A) Immunofluorescent staining of Wnt3a in DU145 PTEN-KD treated with avasimibe (10 µM,
2 days) or IWP-2 (10 µM, 1 day). Arrows indicate membrane localized Wnt3a. Green:
Wnt3a, Blue: DAPI. Scale bar: 25 µm. Insert scale bar: 10 µm. (B) Quantification of cells
with membrane Wnt3a after avasimibe or IWP-2 treatment as indicated in (A). (C)
Immunoblot of antibodies against Wnt3a and β-actin in DU145 PTEN-KD treated with
avasimibe (10 µM, 2 days). Medium Wnt3a was immunoprecipitated and normalized by
precipitated protein concentration. (D) Representative images of migration of cells pretreated with avasimibe (10 µM, 2 days) and subsequent Wnt3a supplement (100 ng/mL).
Red: propidium iodide staining. Scale bar: 50 µm. (E) Quantitation of migrated cells
shown in (D). Error bars represent SD (n = 3). ***p < 0.0005. (F) Schematic showing the
molecular mechanism. In metastatic PCa, high level of lipid synthesis and/or uptake
provides fatty acid substrates for Wnt acylation. This process is accompanied by
conversion of excess cholesterol to CE by ACAT and stored in LDs. Wnt acylation
allows secretion and binding of Wnt to the membrane to drive cell migration and
invasion. Suppressing cholesterol esterification by ACAT inhibition downregulates
SREBP through negative feedback loop. As a result, lipogenesis pathway is suppressed,
which limits the availability of free fatty acids required for Wnt acylation. Metastasis is
then inhibited by reduced secretion of Wnt protein.
SFA: saturated fatty acid, MUFA: unsaturated fatty acid, LD: lipid droplet.

49

Wnt3a/DAPI

.~

\
~

•

Avasimibe

•

•

#

.

.•

:

·•

~-

I

• ••

\

C

B

._;-..

-~

'.'I .... ..

/

IWP-2

Lysate
Ctrl Ava

----,,

Medium IP
Ctrl Ava

Wnt3a
Actin

% with membrane Wnt3a

Control

A

100
80

40

1.0

0.7

***

20
0

Wnt3a

Ratio

n.s.

60

Ctrl

E

Ava

***
IWP-2

*** ***

1--------1

Migrated cells

Migrated cells (%)

D

-

Avasimibe
Wnt3a

F

+

+
+

-

Wnt

Wnt

100
75
50
25

0
Avasimibe
Wnt3a

-

+
-

+
+

Wnt

Wnt

SREBPs

LD

ACAT

•

SFA

Cholesterol
Acyl CoA

•

MUFA

SREBPs

LD

Acylation

ACAT

SFA

Cholesterol

Acyl CoA

MUFA

Acylation

50
The intra-cardiac injection mouse model introduces the tumor cells directly into circulation, thus
emphasizes the survival and growth of PCa cells in other organs. Thus, we used this model to
evaluate therapeutic efficacy of CE depletion in mice with metastatic PCa already developed. Our
results indicate that Avasimin treatment effectively suppressed growth of metastatic PCa in
multiple organs. Importantly, we did not observe detectable toxicity from Avasimin to the animals.
This is because CE content is usually low in most normal cell types [9, 63], giving a unique
opportunity to specifically target PCa cells without causing unfavorable disturbance to the
cholesterol homeostasis in most of normal cells. Indeed, there is an increasing body of evidence
showing accumulation of CE in various types of cancer, including prostate cancer [88], breast
cancer [229], leukemia [230, 231], glioblastoma [232], and pancreatic cancer [109]. These studies
collectively support the importance of the cholesterol storage pathway in malignancy.

We observed reduced free monounsaturated fatty acid levels after ACAT inhibition. We suspect
that as a consequence of inhibiting cholesterol esterification, free cholesterol level is increased,
which downregulates SREBP activities through sterol-dependent negative feedback loop [8]. This
is supported by our previous finding that expression and cleavage of SREBP-1c are reduced upon
CE depletion [88]. As SREBP-1c is the isoform that mainly promotes fatty acid biosynthetic
pathway [49, 50], our observation of decreased fatty acid levels after inhibiting cholesterol
esterification is likely to be through the regulation of SREBP-1c. Importantly, it has been reported
that depleting SREBP results in reduction in the monounsaturated fatty acids in the cellular pool
of free fatty acids [233], which supports our hypothesis. As the enzyme catalyzing the rate-limiting
step in unsaturated fatty acid synthesis, SCD1, is directly regulated by SREBP-1c [51, 52], it is
possible that the level of monounsaturated fatty acids is reduced by downregulation of SCD1.
Overall, given that SREBP-1 has been proposed to be an important regulator that provides a link
between oncogenic signaling and tumor metabolism [233, 234], we believe that SREBP-1 plays
an essential role in lipid homeostasis in during PCa progression.

Finally, our results reveal that lipid metabolism is an important regulator of Wnt activity. Several
studies show that Wnt acylation by acyltransferase Porcupine is essential for its secretion and
binding to membrane receptors [218, 221, 235]. In a recent study, alterations in the Wnt signaling
pathway were observed in 18% of patients with metastatic castration-resistant PCa [236].
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Interestingly, it was reported that patients with alterations in these genes are predicted to respond
to Porcupine inhibitors, such as IWP-2 [235], which supports the importance of Wnt acylation in
PCa progression. During acylation, a sufficient fatty acid pool is as critical as the expression of
involved proteins. In support of this concept, overexpression of fatty acid synthase was shown to
promote palmitoylation of Wnt protein in human prostate epithelial cells [237]. In our study, we
show that palmitoleic acid level regulates Wnt secretion in PCa, which is essential for cell
migration (Figure 3.11 and 3.12). Collectively, these results show an important crosstalk between
lipid metabolism and Wnt signaling, which work cooperatively to promote PCa metastasis.
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3.

ASSESSING CHOLESTEROL STORAGE IN LIVE CELLS AND C.
ELEGANS BY SRS IMAGING OF PHENYL-DIYNE CHOLESTEROL

The work presented in this chapter was published in Scientific Reports [189]. Reprinted with
permission from [189]. Copyright © 2015 Nature Publishing Group.

Here, we report a cholesterol imaging method using rationally synthesized phenyl-diyne
cholesterol (PhDY-Chol) and SRS microscope. The phenyl-diyne group is biologically inert and
provides a Raman scattering cross section that is 88 times larger than the endogenous C=O
stretching mode. SRS microscopy offers an imaging speed that is faster than spontaneous Raman
microscopy by three orders of magnitude, and a detection sensitivity of 31 µM PhDY-Chol (~1,800
molecules in the excitation volume). Inside living Chinese hamster ovary (CHO) cells, PhDYChol mimics the behavior of cholesterol, including membrane incorporation and esterification. In
a cellular model of NP-C disease, PhDY-Chol reflects the lysosomal accumulation of cholesterol,
and shows relocation to LDs after HPβCD treatment. In living C. elegans, PhDY-Chol mimics
cholesterol uptake by intestinal cells and reflects cholesterol storage. Together, our work
demonstrates an enabling platform for study of cholesterol trafficking in living cells and organisms.

Introduction
As an important component of cellular membrane, cholesterol controls physical properties of the
membrane and contributes to specific membrane structures such as lipid rafts [1, 2]. Inside cells,
cholesterol plays an important role in various signaling pathways [4, 5] serves as the precursor for
signaling molecules, and modifies specific proteins, such as hedgehog, to control protein
trafficking and activity [6]. The distribution of cholesterol in a living cell is highly regulated [8,
10]. Intracellular cholesterol is stored in LDs in the form of CE to avoid the toxicity caused by free
cholesterol [62, 63]. Dysregulation of cholesterol metabolism and/or trafficking has been linked
to diseases, including atherosclerosis [32, 62], NP-C disease [72], and various cancers [88, 238].
So far, our understanding of cholesterol transport and metabolism is limited, partly due to lack of
suitable tools for imaging cholesterol in a living system [9].
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Intracellular cholesterol transport and metabolism have been studied extensively using various
reporter molecules [112], including cholesterol binding molecules and cholesterol analogs.
Cholesterol binding molecules, such as cholesterol oxidase, filipin, and perfringolysin O
derivatives, are commonly used to study steady-state distribution of cholesterol in fixed cells and
tissues [113-115]. Fluorescent cholesterol, including intrinsic fluorescent sterols such as DHE and
fluorophore-tagged analogs such as NBD-cholesterol and BODIPY-cholesterol are widely used in
vitro and in vivo

[117, 119, 120]. Radiolabeled cholesterol or its precursors are used in

biochemical studies of metabolism and trafficking of cholesterol [112]. More recently, clickable
cholesterol analogs were also developed for studying cholesterol-binding proteins and tracking
cholesterol metabolism and distribution [122, 123].

These current cholesterol assays have limitations. Cholesterol oxidase is commonly used in
fluorometric or colorimetric assays to quantify total cholesterol in homogenized cells.
Radiolabeled cholesterol has to be used in combination with separation methods to determine
intracellular cholesterol distribution indirectly. For imaging purpose, filipin is the most commonly
used molecule for visualizing distribution of free cholesterol, but it is only applicable to fixed cells
or tissues with moderate specificity because filipin also labels other lipids [239]. BODIPYcholesterol is known to cause perturbations due to bulkiness of the fluorophores [121]. DHE has
the closest structure as cholesterol, but its fluorescence undergoes rapid photo-bleaching [112],
which impedes real-time observation of cholesterol trafficking. Clickable cholesterol analog
requires additional steps before fluorescence imaging.

Owing to smaller volumes compared to fluorophores, Raman tags provide a promising way of
imaging biomolecules like DNA and cytochrome c inside cells on a Raman microscope [185, 240].
These Raman tags utilize the vibrational signatures of the carbon-deuterium (C-D) bond, the cyano
bond (CN) or the alkyne bond (CC) that are spectrally isolated from the endogenous Raman
bands [241]. Spontaneous Raman imaging has allowed cellular trafficking of different C-D labeled
lipid species in fixed cells [242], and direct visualization of alkyne-tagged DNA synthesis and
cytochrome c release from mitochondria in living cells [185, 240] with an image acquisition speed
of 50 min per frame of 127 × 127 pixels. To enhance the signal level, nonlinear vibrational
microscopy based on the coherent Raman process has been developed [129] and deployed for
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imaging C-D labeled fatty acids [141, 243], amino acids [179], and drugs [244] in living cells with
a speed that is ~1,000 times faster than with spontaneous Raman microscopy. More recently, SRS
imaging of alkyne-tagged molecules has been reported, with a detection limit at the level of
hundreds of micromolar [186, 187]. SRS is a third order nonlinear optical process that involves
two laser fields, namely, a pump field at p and a Stokes field at S. When the beating frequency
(p S) is tuned to excite a molecular vibration, the energy difference between p and S pumps
the molecule from a ground state to a vibrationally excited state. In correspondence, the laser fields
experience a weak decrease in pump beam intensity, called SRL, and a corresponding increase in
Stokes beam intensity, called SRG. In the case of SRL, the Stokes beam intensity IS is modulated
and the pump beam intensity Ip is recorded by a photodiode. The induced modulation is often
extracted by a lock-in amplifier. Theoretically, the modulation depth induced by SRL, ISRL/Ip, is
linearly proportional to the Raman cross section, , molar concentration of the target molecule, N,
and the Stokes beam intensity, i.e., ISRL/Ip   N IS. SRS microscopy offers much faster imaging
speed compared to spontaneous Raman microscopy [133].

Here, we report the synthesis of a Raman probe, PhDY-Chol, and its use for imaging cholesterol
esterification, storage and trafficking inside living cells and vital organisms. By rational design
and chemical synthesis, we prepared a probe molecule, PhDY-Chol, which gives a 2254 cm-1
Raman peak that is 88 times stronger than the endogenous C=O stretching band. Compared to
alkyne-tagged cholesterol of which the IC50 is 16 µM, the phenyl-diyne group is biologically inert
and did not cause cytotoxicity after 16 h incubation at 50 µM. In living CHO cells, SRS imaging
showed incorporation into plasma membrane, esterification of PhDY-Chol by ACAT, and storage
in LDs. In a cellular model of NP-C disease, PhDY-Chol is selectively accumulated in lysosomes
and is esterified and relocated to LDs after treatment with a cholesterol-mobilization drug. In live
C. elegans, SRS imaging of PhDY-Chol reflected cholesterol uptake through ChUP-1 regulated
manner, and storage in the intestinal cells. These studies herald the potential of our method for
unveiling intracellular cholesterol trafficking mechanisms and highly efficient screening of drugs
that target cholesterol metabolism.
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Experimental section
3.2.1 Calculation of Raman intensity
All calculations were performed at the HF/6-311G* level of theory. Geometry optimizations,
vibrational frequencies and Raman intensities are obtained in Q-Chem electronic structure package
[245]. Localized polarizabilities are calculated in the GAMESS quantum chemistry software [246].
3.2.2 Chemicals
3β-hydroxy-Δ5-cholenic acid was purchased from VWR. Lipoprotein-deficient serum was
purchased from Biomedical Technologies Inc. Cholesterol, avasimibe, and filipin complex were
purchased from Sigma-Aldrich. BODIPY-cholesterol was purchased from Avanti Polar Lipids,
Inc. Propidium iodide, BODIPY, and LysoTracker were purchased from Life technologies.
3.2.3 Synthesis of Raman-tagged cholesterol
A series of tagged cholesterols – alkyne cholesterol (A-Chol, 5), phenyl-alkyne cholesterol (PhAChol, 6), phenyl-diyne cholesterol (PhDY-Chol, 7), and cyano cholesterol (CN-Chol, 8), was
synthesized as shown in Figure 4.1. Our synthesis commenced with commercially available
cholenic acid 3. Using a sequence of THP-protection, LiAlH4 reduction, Dess-Martin oxidation
and Seyferth-Gilbert-Bestmann homologation, cholenic acid 3 was converted to compound 4 with
a terminal alkyne group in excellent yield. Removal of the THP-protecting group gave probe 5.
We further prepared PhA-Chol 6 and PhDY-Chol 7 from compound 4 via a palladium-catalyzed
Sonogashira reaction and a copper-catalyzed Cadiot-Chodkiewicz reaction, respectively, followed
by acidic removal of THP group. Additionally, CN-Chol 8 was prepared from cholenic acid 3 via
standard transformations.
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Figure 3.1 Design and synthesis of tagged cholesterol probes.
Reagents and conditions:
a) DHP (5.0 equiv), p-TsOH (0.2 equiv), THF, RT, 91%;
b) LiAlH4 (3.0 equiv), THF, 0 °C to RT, 98%;
c) DMP (3.0 equiv), NaHCO3 (3.0 equiv), CH2Cl2, 0 °C, 86%;
d) dimethyl (1-diazo-2-oxopropyl)phosphonate (Bestmann reagent, 2.4 equiv), K2CO3
(4.0 equiv), THF/MeOH, RT, 99%;
e) p-TsOH (1.0 equiv), THF/MeOH, RT, 84%;
f) Iodobenzene (1.02 equiv), PdCl2(PPh3)2 (0.05 equiv), CuI (0.05 equiv), TEA, RT; then
p-TsOH (1.0 equiv), THF/MeOH, RT, 77%;
g) CuI (0.1 equiv), K2CO3 (2.0 equiv), P(o-Tol)3 (0.2 equiv), phenyl bromoacetylene (1.3
equiv), EtOH, 100 °C, 51%;
h) p-TsOH (1.0 equiv), THF/MeOH, RT, 95%;
i) MsCl (3.0 equiv), TEA (3.0 equiv), CH2Cl2, 0°C to RT, 75%;
j) KCN (2.0 equiv), DMSO, 90°C, 76%;
k) p-TsOH (1.0 equiv), THF/MeOH, RT, 74%. DHP = 3,4-Dihydro-2H-pyran, DMP =
Dess-Martin Periodinane, p-TsOH = p-Toluenesulfonic acid, TEA = triethylamine, P(oTol)3 = tri(o-tolyl)phosphine, MsCl = methanesulfonyl chloride.
CN: cyano; A: alkyne; PhA: phenyl-alkyne; PhDY: phenyl-diyne; Chol: cholesterol.
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3.2.4 Solubilization of tagged cholesterol
To solubilize the tagged cholesterol molecules, the following procedure was used to prepare a
stock solution of 10 mM cholesterol probe molecules. The appropriate amount of cholesterol probe
powder was dissolved in 100% ethanol to make a 20 mM-solution. The tube was vortexed and
then sonicated in bath sonicator for 2 min. The same volume of DMSO was added into the tube,
vortexed, and then sonicated in bath sonicator for 2 min. BODIPY-cholesterol was prepared with
the same procedure. For SRS imaging and Raman spectral analysis of tagged cholesterol solutions,
cholesterol probe molecules were prepared in cyclohexanone at 50 mM. The tube was vortexed
and then sonicated in bath sonicator for 2 min. 1 µL of the solution was taken to prepare cover
glass samples immediately before use.
3.2.5 Cell culture and PhDY-Chol treatment
CHO-K1 cells and M12 cells (mutant CHO-K1 cells that contain a deletion of the NPC1 locus
[247]) were kindly provided by Dr. Daniel Ory, and were grown in a monolayer at 37˚C in 5%
CO2 in DMEM/F-12 medium supplemented with 10% (vol/vol) FBS. To incubate cells with
PhDY-Chol, cells were pre-incubated in DMEM/F-12 medium supplemented with 4.4%
lipoprotein-deficient serum to deplete medium cholesterol for 16 hr. The cells were then incubated
with PhDY-Chol containing medium (DMEM/F-12 + 4.4% lipoprotein-deficient serum + 50 µM
PhDY-Chol) for 16 h to 24 hr. Cells were rinsed with 1x PBS buffer three times before the next
procedure.
3.2.6 Raman spectromicroscopy
The background of Raman spectrum was removed as described [200]. Each Raman spectrum of
tagged cholesterol solution was acquired in 10 seconds, and each Raman spectrum of fluorescence
stained cells was acquired in 30 seconds. On the same microscope, TPEF imaging was performed
with 707 nm laser with 100 mW power. Backward-detected two-photon fluorescence signal was
collected through a 425/40 nm or 522/40 nm band-pass filter for imaging filipin or BODIPY
fluorescence, respectively.
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3.2.7 SRS microscopy
SRS imaging was performed on a femtosecond SRL microscope, with the laser beating frequency
tuned to the CC vibration band at 2252 cm-1, or to the C-H vibration band at 2885 cm-1, as
described previously [141]. The laser power at the specimen was maintained at 75 mW, and no
cell or tissue damage was observed. For off-resonance, 2099 cm-1 was used. On the same
microscope, TPEF imaging was performed with 843 nm laser with 30 mW power. Forwarddetected two-photon fluorescence signal was collected through an appropriate band-pass filter for
imaging filipin, BODIPY, or LysoTracker.
3.2.8 ACAT-1 inhibition
ACAT-1 inhibition was used to block cholesterol esterification either by adding a potent ACAT
inhibitor, avasimibe, or by RNA interference with ACAT-1 shRNA plasmid. Avasimibe: Cells
were pre-treated with avasimibe at a final concentration of 10 µM for 24 hr. Then PhDY-Chol
containing medium with 10 µM avasimibe was added into the cells and incubated for 24 hr. RNA
interference: RNA interference was employed to specifically inhibit endogenous ACAT-1. The
ACAT-1 shRNA plasmid was purchased from Santa Cruz (sc-29624-SH). shRNA plasmid was
transfected with Lipofectamine®2000 (Invitrogen 11668030) as described in the manufacturer’s
protocols.
3.2.9 hydroxypropyl β-cyclodextrin (HPβCD) treatment
HPβCD was used as a drug treatment of NP-C disease. M12 cells were incubated with PhDY-Chol
for 16 hr as described above. Then cells were treated with 500 µM HPβCD for 30 hr.
3.2.10 Cell viability assay
CHO cells were grown in 96-well plates with density of 4,000 cells per well. The next day, the
cells were treated with each cholesterol probe at the indicated concentrations for 48 hr. Cellviability was measured with the MTT colorimetric assay (Sigma).
3.2.11 Propidium iodide staining
Propidium iodide was used to stain late apoptotic or necrotic cells. CHO cells were incubated with
30 µM of tagged cholesterol molecules for 24 hr. The propidium iodide staining was performed
following protocols provided by the manufacturer (Life Technologies).
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3.2.12 Fluorescent staining of free cholesterol, LDs, and lysosomes
Filipin was used to stain free cholesterol. Cells were fixed with 10% formalin solution (Sigma) for
1 hr at room temperature. 1.5 mg/mL glycine in PBS was used to quench the formalin by
incubating the fixed cells for 10 min at room temperature. To stain the cells with filipin, working
solution of 0.05 mg/mL of filipin in PBS/10% FBS was used to incubate cells for 2 hr at room
temperature. BODIPY was used to label LDs. Cells were incubated with 10 µg/mL of BODIPY
for 30 min at room temperature. LysoTracker Yellow-HCK-123 was used to stain lysosomes
following protocols provided by the manufacturer (Life Technologies). Cells were rinsed with PBS
three times before TPEF imaging.
3.2.13 C. elegans strains
The N2 Bristol was used as wild-type strain. VC452 strain with chup-1(gk245) X genotype was
used to study PhDY-Chol uptake. VS17 strain with hjIs9 [ges-1p::glo-1::GFP + unc-119(+)]
genotype was used to study cholesterol storage in worms.
3.2.14 PhDY-Chol uptake into C. elegans
PhDY-Chol uptake procedure was modified from a previously reported procedure [119]. Briefly,
500 µM of PhDY-Chol in DMSO was spread on the NGM plates seeded with an E. coli OP50
lawn and allowed to grow overnight at room temperature. C. elegans was then transferred to
PhDY-Chol containing plates and grown for 3 days before SRS imaging.
3.2.15 Statistical analysis
To quantify PhDY-rich area, we first selected one cell and used “Threshold” function to select
PhDY-rich cellular regions using ImageJ. Then, by using “Analyze Particles” function, the area
fraction (%) of PhDY-rich region was obtained. To quantify PhDY-rich LDs, “Image Calculator”
function in ImageJ was used to multiply SRS image of PhDY-Chol by TPEF image of BODIPY.
Then, after using “Threshold” function to select PhDY-rich LDs, the number of PhDY-rich LDs
was counted by “Analyze Particles” function. For each group, 7 cells were analyzed, and results
were shown as mean ± SD. Student’s t-test was used for all the comparisons. p < 0.05 was
considered statistically significant.
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Results
3.3.1 Rational design and synthesis of tagged cholesterol with an extremely large Raman
scattering cross section
In order to design a probe molecule that not only maintains physiological functions of cholesterol,
but also has a large Raman scattering cross section, we chose to replace the aliphatic side chain of
cholesterol with a cyano or an alkynyl group (Figure 4.1). These groups have small size, which
could minimize structural perturbation of the molecule of interest, in this case, cholesterol.
Meanwhile, these groups produce strong Raman scattering peaks in a cellular silent region (1800
– 2800 cm-1) [240, 241] and therefore, can potentially be used for Raman imaging in a lowconcentration condition. It has been reported that as the chain length increases, the
hyperpolarizability increases in polyynes [248]. Also, aromatic ring capped alkyne was shown to
give stronger Raman signals than terminal alkyne [185]. To design tagged cholesterol with very
strong Raman intensity, we calculated the Raman cross section of potential tags, namely alkyne,
phenyl-alkyne, diyne, and phenyl-diyne, using the Q-Chem and GAMESS electronic structure
packages to provide insight of the relation between molecular structure and Raman intensity. Our
results show that the localized polarizabilities on each CC moiety increase with the number of
conjugated triple bonds, as well as with addition of a phenyl ring (Figure 4.2A and Table 4.1).
Thus, the total polarizability of the molecule increases as a result of the additive effect as well as
non-linear boost in the polarizability of conjugated bonds. The phenyl ring serves as both a donor
and an acceptor of -electrons from the neighboring triple bonds, further escalating polarizabilities
of neighboring conjugated bonds. Taking into account that the Raman intensity is proportional to
squares of polarizability derivatives, the additional three-fold enhancement of the total
polarizability due to conjugation results in a ~10-fold boost in Raman intensity. Together,
compared to the alkyne group, the Raman intensity increases by 9 times by adding a phenyl group
to the terminal alkyne, and 52 times by conjugating a phenyl group and another alkyne (Figure
4.2B). Based on the above considerations, we have synthesized a series of tagged cholesterols –
alkyne cholesterol (A-Chol, 5), phenyl-alkyne cholesterol (PhA-Chol, 6), phenyl-diyne cholesterol
(PhDY-Chol, 7), and cyano cholesterol (CN-Chol, 8), as shown in Figure 4.1.
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Figure 3.2 Theoretical Raman intensities of the CC stretching mode in various tags.
The total molecular polarizability is broken down in terms of the value of the polarizability
corresponding to each bond in the molecule. The Raman scattering cross section arises
from the polarizability caused by conjugation of the -electrons of the alkyne and the
phenyl groups. The -orbitals possess large polarizability tensors, such that the
polarizability of the triple bond is mainly determined by the polarizability of -orbitals.
(A) Depiction of symmetry-localized -orbitals in C4H-C6H5 (CC-CC-Ph). The
distributed polarizabilities corresponding to the localized orbitals on CC and phenyl ring
are shown in Table 4.1, such that the polarizabilities of orbitals 1 and 2 determine the
total polarizability of the left CC bond, polarizabilities of orbitals 3 and 4 sum up to the
polarizability of the middle CC bond. Additionally, the closest to alkyne part of the ring
(orbital 5) exhibits significant change in polarizability along triple-bond stretching
vibration, and therefore polarizabilities corresponding to this orbital are included in the
total count of polarizability of the triple-bond system. Distributed polarizabilities are
calculated using GAMESS electronic structure package [246]. (B) Comparison of CC
stretching Raman intensities in various tags computed using the Q-Chem quantum
chemistry software [245]. Intensities were normalized to the highest intensity.

63

A

B
Cal.

9.0 x 10-4

0.019

a1et

0.17

a1ph1et

0.17

a2et
a2ph1et

1.0
1.0

a1

0.8

0.6

0.4

Norm. calculation (a.u.)

0.2

0.0

64

Table 3-1 Distributed polarizabilities of CC and phenyl moieties calculated as sums of
polarizabilities of localized π-orbitals in various tags[b]
XX[a]

average

CC

2.82

1.60

CC-Ph

7.42

3.76

CC

4.62

2.15

Ph

2.80

1.61

CC-CC

8.70

3.54

CC

4.35

1.77

CC

4.35

1.77

CC-CC-Ph

16.70

7.37

left CC

5.77

2.51

middle CC

7.20

2.95

Ph

3.73

1.91

[a] XX: the largest components
[b] The total polarizability of -conjugated
system increases as a result of the additive
effect as well as non-linear boost in the
polarizability of conjugated bonds.
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3.3.2 Raman spectral analysis and SRS imaging of tagged cholesterol
To determine the Raman shift of the CC stretching vibrational mode and to compare the level of
Raman signals from the tagged cholesterols, we prepared 50 mM of each compound in
cyclohexanone and performed confocal Raman spectral analysis (Figure 4.3). The signal from
CN-Chol was too weak to be detected. A-Chol showed its peak for CC vibrational mode at 2122
cm-1; PhA-Chol at 2239 cm-1; PhDY-Chol at 2254 cm-1 (Figure 4.3A). To evaluate the amplitude
of the Raman scattering cross section, we fitted each Raman band with a Lorentzian profile and
calculated the area under the fitted profile. Compared to the Raman peak of each tag to the 1714
cm-1 C=O Raman peak from the solvent (9.7 M for pure cyclohexanone), the alkyne, PhA, and
PhDY groups were found to be 6, 15, and 88 times stronger in Raman cross section, respectively
(Figure 4.3B). This result showed that the PhDY tag produces a spectrally-isolated peak, which is
stronger than the C=O vibrational mode by two orders of magnitude.

To determine the SRS imaging sensitivity for PhDY-Chol, we used a femtosecond SRL
microscope reported elsewhere [141]. Cyclohexanone solutions of PhDY-Chol were prepared by
serial dilution, and SRS images of PhDY-Chol were recorded with the laser beating frequency
tuned to be resonant with CC vibration at 2254 cm-1. In solutions without PhDY-Chol, a residual
background was detected, caused by cross-phase modulation. The SRS contrast, defined as (S 
B) / B, where S and B denote SRS signal and background, was calculated as a function of PhDYChol molar concentration. At the speed of 200 µs per pixel, a linear relationship was observed
(Figure 4.3C) and 13% and 4% contrasts were reached at 313 µM and 156 µM, respectively. To
increase the detection sensitivity, we chirped the femtosecond lasers to 0.8 picoseconds with a SF10 glass rod. This spectral focusing approach [151] maintained 85% of the SRS signal while
reduced the cross-phase modulation background level by 3 times, to a level of 6.3 × 10-7 in terms
of modulation depth. As a result, the SRS contrast became 14% at 31 µM, corresponding to ~1,800
molecules in the excitation volume (Figure 4.3D). We also depicted the modulation depth (I/I)
as a function of molar concentration (Figure 4.4), which is used for estimating the molar
concentration of PhDY-Chol inside cells in following studies.
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Figure 3.3 Raman spectral analysis of tagged cholesterol and SRS detection of PhDY-Chol.
(A) Raman spectra of 50 mM tagged cholesterols in cyclohexanone (solvent). Spectral intensity
was normalized by C=O vibration band at 1714 cm-1. Spectral acquisition time: 10 s. (B)
Plot of relative intensity of Raman tags versus solvent and Raman shifts of tagged
cholesterols. Based on the molar concentration of the molecules (50 mM) and the solvent
(9.7 M), the Raman cross section of CC from A-Chol, PhA-Chol, and PhDY-Chol are 6
times, 15 times, and 88 times larger than the C=O band from the solvent, respectively.
CN: cyano; A: alkyne; PhA: phenyl-alkyne; PhDY: phenyl-diyne; Chol: cholesterol. (C)
SRS contrast versus concentration plot of PhDY-Chol solutions. 13% contrast was
reached at 313 µM and 4% contrast was reached at 156 µM. Image acquisition speed:
200 µs per pixel. Data represents the mean ± SEM in 3 measurements. R2 = 0.996. (D)
SRS contrast versus concentration plot of PhDY-Chol solutions using chirped
femtosecond lasers with spectral focusing approach. 14% contrast was reached at 31 µM.
Image acquisition speed: 200 µs per pixel. Data represents the mean ± SEM in 3
measurements. R2 = 0.980. Contrast was defined as (S - B) / B. S: SRS signal; B:
background.

67

10

I/I (x10-6)

10 mM

1

1
Concentration (mM)

10

Figure 3.4 Linear correlation between PhDY-Chol concentration and modulation depth.
Concentration of PhDY-Chol and modulation depth (ΔI/I) show linear correlation, which can be
expressed as: y = 0.85x – 5.77 (R2 = 0.98). Inset is an SRS image of 10 mM PhDY-Chol
in cyclohexanone. Data acquisition speed: 200 µs per pixel. Error bars represent SEM.
3.3.3 Cytotoxicity caused by terminal alkyne is avoided by phenyl group
To evaluate the cytotoxicity of tagged cholesterols, we performed MTT cell-viability assays after
treating CHO cells with tagged cholesterol. Various concentrations of tagged cholesterol were
added to the culture media and the cells were incubated for 48 hr before the assays were conducted.
A-Chol was found to be toxic to the cells with IC50 of 16 µM. Importantly, adding a phenyl group
effectively reduced the cytotoxicity (Figure 4.5A). To directly visualize the toxic effect, we
stained the cells with propidium iodide for late apoptosis and necrosis. Cells incubated with AChol showed reduced density and extensive apoptosis, whereas both PhA-Chol and PhDY-Chol
caused minimum cell death (Figure 4.5B). This result presents another important role of the
phenyl group, which is to reduce the toxicity caused by terminal alkyne. Based on the signal level
and the severity of toxicity, we conclude that PhDY-Chol is the most suitable cholesterol analog
for live-cell imaging, and we used PhDY-Chol in subsequent experiments.
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Figure 3.5 Phenyl group prevented cytotoxicity of the probe molecules.
(A) MTT Cell-viability assays. CHO cells were incubated with each probe in various
concentrations for 48 hr before MTT cell-viability assays were conducted. Error bars
represent SEM. n > 3, *: p < 0.05; **: p < 0.005; ***: p < 0.0005. (B) Propidium iodide
staining for visualizing apoptosis and necrosis. Transmission images show reduced cell
number in A-Chol treated CHO cells. A-Chol: alkyne cholesterol; PhA-Chol: phenylalkyne cholesterol; PhDY-Chol: phenyl-diyne cholesterol; PI: propidium iodide. Scale
bar: 50 µm.
3.3.4 Membrane incorporation and esterification of PhDY-Chol in living cells
We chose CHO cells which are commonly used for cholesterol trafficking and metabolism studies
[249]. To enhance cellular uptake of PhDY-Chol, the cells were pre-incubated in medium
supplemented with lipoprotein-deficient serum to deplete medium cholesterol, after which the cells
were incubated with 50 µM PhDY-Chol for 16 hr. By tuning the laser beating frequency to be
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resonant with CC vibration (2254 cm-1), SRL signals arose from PhDY-Chol. We also tuned the
laser to be resonant with C-H vibration (2885 cm-1) and obtained signals from C-H-rich lipid
structures, such as LDs.

To show the incorporation of PhDY-Chol into the plasma membrane, we performed spectral
focusing SRS imaging of living CHO cells after treating with PhDY-Chol for 1 hr with 6 µs per
pixel speed. PhDY-Chol in the membrane was detected in the on-resonance image, and the contrast
disappeared in the off-resonance image (Figure 4.6A). The membrane incorporation was
confirmed by filipin staining of free cholesterol and Raman spectral analysis (Figure 4.6B and C).
By focusing at the filipin-stained membrane, we have obtained the Raman spectrum showing the
C=C band from filipin (Figure 4.6D), the amide I band from protein, and the CC band from the
PhDY (Figure 4.6C). Inside living CHO cells, PhDY-Chol was colocalized with LDs found in the
C-H vibrational region (Figure 4.7A). This colocalization was confirmed by TPEF imaging and
Raman spectral analysis of BODIPY-stained LDs in fixed CHO cells. (Figure 4.8). The Raman
spectra of the BODIPY-labeled LDs showed a 702 cm-1 peak from cholesterol ring and the CC
band from the PhDY (Figure 4.8B), which further supports the localization of PhDY-Chol in LDs.
Importantly, high imaging speed offered by SRS microscopy allowed real-time imaging of the
trafficking of PhDY-Chol containing LDs within living cells.
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Figure 3.6 PhDY-Chol is incorporated into cellular membrane.
(A) SRS images of living CHO cells treated with PhDY-Chol for 1 hr. PhDY-Chol was seen in
plasma membrane and intracellular structures. Data acquisition time: 6 µs per pixel for
512 × 512 pixels. Scale bar: 10 µm. (B) TPEF image of filipin-labeled CHO cells. Arrow
indicates the point used for Raman spectral analysis. Red intensity bar represents the
relative intensity of fluorescence. Scale bar: 10 µm. (C) Raman spectrum of filipinlabeled cell membrane acquired on the same TPEF microscope. The bands for filipin,
protein (amide I), and CC vibrational mode are indicated by black arrows. Spectrum
acquisition time: 30 s. (D) Raman spectrum of filipin and the solvent, DMSO. The bands
for filipin is indicated by black arrows. Spectrum acquisition time: 10 s
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Figure 3.7 SRS images of PhDY-Chol in living CHO cells and blockage of PhDY-Chol storage
into LDs via ACAT inhibition.
(A) SRS images of living CHO cells treated with PhDY-Chol (50 µM) for 16 hr. CC vibrational
mode at 2254 cm-1 was used for PhDY-Chol, and C-H vibrational mode at 2885 cm-1 was
used for C-H-rich lipid structures. Lasers were also tuned away to 2099 cm-1 to show
specificity of PhDY-Chol signal inside the cells. PhDY-Chol was found to accumulate in
LDs (arrows). Image acquisition speed: 10 µs per pixel for 512 × 512 pixels. Scale bar:
10 µm. (B) Schematic graph showing the hypothesis of PhDY-Chol metabolism inside
the cells. ACAT: Acyl-CoA:cholesterol acyltransferase. (C) SRS images of PhDY-Chol
in CHO cells and ACAT inhibited CHO cells by avasimibe treatment. As shown in
circles, PhDY-Chol was stored in LDs in CHO cells, but not in avasimibe treated CHO
cells. Image acquisition speed: 100 µs per pixel for 400 × 400 pixels. Scale bar: 10 µm.
Intensity bars in A and C show the ΔI/I of the SRS image. (D) Quantification of PhDYrich and BODIPY-rich LDs in CHO cells before and after ACAT inhibition. The number
of the LDs was normalized by the control group (n = 7). Error bars represent SD. *: p <
0.05. (E) TPEF images of BODIPY-cholesterol and SRS images C-H-rich structures in
CHO cells and ACAT inhibited CHO cells. As shown in circles, BODIPY-cholesterol
showed no difference between the two groups. Scalar bar: 10 µm.
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Figure 3.8 TPEF imaging and Raman spectral analysis to confirm PhDY-Chol storage into LDs.
(A) TPEF image of BODIPY-labeled CHO cells. Arrow indicates the point used for Raman
spectral analysis. Red intensity bar represents the relative intensity of fluorescence. Scale
bar: 10 µm. (B) Raman spectrum of BODIPY-labeled LDs acquired on the same TPEF
microscope. The bands for cholesterol ring, BODIPY, CC, and C-H vibrational modes
are indicated by black arrows. Two representative spectra of LDs are shown. Spectrum
acquisition time: 30 s. (C) Raman spectrum of BODIPY and the solvent, ethanol.
Spectrum acquisition time: 10 s.
It is important to note that PhDY-Chol-rich structures inside the CHO cells could not be stained
by filipin (Figure 4.6B), implicating that it is not in the free form. We hypothesize that PhDYChol is converted into PhDY-CE, by ACAT, the enzyme responsible for cholesterol esterification
[63] (Figure 4.7B). To confirm the esterification of PhDY-Chol, we inhibited ACAT with
avasimibe for 24 hr before addition of PhDY-Chol. After blocking cholesterol esterification, the
amount of PhDY-Chol storage found in CHO cells significantly decreased (Figure 4.7C).
Although LDs were still visible, the amount of PhDY-Chol signal found inside LDs reduced by 4
times (Figure 4.7D). ACAT-1 knockdown by shRNA was also conducted to specifically inhibit
the enzyme. Similarly, we found decreased amount of PhDY-Chol in ACAT-1 knocked down
CHO cells, and the amount of PhDY-Chol in LDs reduced significantly (Figure 4.9A). To
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determine where PhDY-Chol accumulates after ACAT inhibition, we stained the cells with
LysoTracker for lysosomes. Our result indicates that after ACAT inhibition, PhDY-Chol is
partially located in lysosomes (Figure 4.9B). Collectively, these results show that PhDY-Chol can
be transported into cells, converted into PhDY-CE by ACAT-1, and stored in LDs following the
normal metabolic pathway of cholesterol. To emphasize the physiological compatibility of our
PhDY tag, we treated CHO cells with BODIPY-cholesterol. The amount of BODIPY-cholesterol
incorporated into LDs did not change after ACAT inhibition (Figure 4.7D and E), indicating that
BODIPY-cholesterol directly labels the LDs without metabolic conversion into CE. It is known
that excess cholesterol inside cells is stored into LDs through cholesterol esterification by ACAT
proteins [63]. Therefore, PhDY-Chol reflects the intracellular cholesterol metabolism more
faithfully compared to BODIPY-cholesterol.
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Figure 3.9 ACAT inhibition blocks PhDY-CHOL storage into LDs.
(A) SRS images of ACAT-1 knocked down CHO cells. Intensity bar shows the ΔI/I value of the
SRS image. Image acquisition speed: 10 µs per pixel for 400 × 400 pixels. Scale bar: 10
µm. (B) SRS images of PhDY-Chol and TPEF images of LysoTracker-stained organelles
in CHO cells and ACAT inhibited CHO cells by avasimibe treatment. Circles indicate
PhDY-Chol overlapped with LysoTracker-stained organelles. Image acquisition speed:
10 µs per pixel for 400 × 400 pixels. Scale bar: 10 µm.
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3.3.5 Lysosomal accumulation and relocation of PhDY-Chol to LDs in NP-C disease
model
Next, we explored the potential of PhDY-Chol for studying cholesterol transport in NP-C disease,
a disorder featured by abnormal cholesterol accumulation in late endosome/lysosome caused by
mutation in NPC1 or 2 gene [250]. M12 cells, mutant CHO cells that contain a deletion of the
NPC1 locus, were established as a cellular model of the NP-C disease [247]. By combining SRL
imaging of PhDY with TPEF imaging of filipin, we observed that, unlike wildtype CHO cells, the
PhDY-Chol-rich structures were stained by filipin, indicating that these PhDY-Chol molecules are
located in lysosomes. (Figure 4.10A, Figure 4.11A and B). Moreover, we observed some filipin
labeled structures that do not contain PhDY-Chol. This result is reasonable given that filipin has
been shown to label other lipid molecules, such as glycosphingolipids [239]. As additional
evidence, we incubated M12 cells with PhDY-Chol and stained the cells with LysoTracker. It was
found that all PhDY-Chol-rich areas were localized in LysoTracker-stained organelles (Figure
4.11C). Collectively, these results showed that PhDY-Chol selectively represents the lysosomal
storage of cholesterol in the NP-C disease model.
We then treated the PhDY-Chol-labeled M12 cells with a cholesterol-mobilizing drug, HPβCD
[251]. This drug is known to mediate lysosomal escape of cholesterol, and promote storage of
excess cholesterol into LDs [252]. After treating with HPβCD, the amount of PhDY-Chol in M12
cells decreased by half (Figure 4.10B and C). Interestingly, we observed that some PhDY-Cholrich areas were not labeled by filipin after HPβCD treatment (arrow heads in Figure 4.10B). These
areas likely represent PhDY-CE stored in LDs. To confirm this possibility, we stained the cells
with BODIPY for localization of LDs. The result clearly showed that PhDY-Chol has moved into
LDs after HPβCD treatment, and the number of PhDY-rich LDs increased significantly (Figure
4.10D and E). Together, these data indicate that PhDY-Chol can be used as a reliable cholesterol
analog to study cholesterol mobilization inside living cells.
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Figure 3.10 Restored cholesterol transport in M12 cells treated with HPβCD.
TPEF images of filipin and SRS images of PhDY-Chol in (A) PhDY-Chol-loaded M12 cells, and
(B) the same cells treated with HPβCD (500 µM) for 30 h. Arrows indicate PhDY-rich
area labeled by filipin before treatment (non-esterified PhDY-Chol), and arrow heads
indicate PhDY-rich area not labeled by filipin after treatment (esterified PhDY-Chol). (C)
Quantification of PhDY-rich area in the cells before and after HPβCD treatment (n = 7).
(D) TPEF images of BODIPY and SRS images of PhDY-Chol in M12 cells treated with
or without HPβCD (500 µM) for 30 h. Arrow heads indicate LDs without PhDY-Chol
before treatment, and arrows indicate LDs with PhDY-Chol after treatment. (E)
Quantification of PhDY-rich LDs in the cells before and after HPβCD treatment (n = 7).
Green intensity bar shows the ΔI/I value of the SRS image; red intensity bar represents
the relative intensity of fluorescence. Image acquisition speed: 100 µs per pixel for 400 ×
400 pixels. Scale bar: 10 µm. Error bars represent SD. *: p < 0.05, ** : p < 0.005.
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Figure 3.11 PhDY-Chol reflects lysosomal cholesterol accumulation in M12 cells.
(A) TPEF image of filipin-labeled M12 cells. Arrow indicates the point used for Raman spectral
analysis. Red intensity bar represents the relative intensity of fluorescence. (B) Raman
spectrum of the filipin-labeled organelle acquired on the same TPEF microscope. The
bands for cholesterol ring, filipin, protein (amide I), and CC vibrational mode are
indicated by black arrows. Spectrum acquisition time: 30 s. (C) SRS image of PhDYChol and TPEF image of LysoTracker-stained organelles in M12 cells. All PhDY-CHOL
was found inside lysosomes. Arrows representatively indicate that PhDY-Chol is
accumulated in lysosomes. Intensity bar shows the ΔI/I value of the image. Image
acquisition speed: 10 µs per pixel for 400 × 400 pixels. Scale bar: 10 µm.
3.3.6 Cholesterol uptake and storage in intestinal cells in C. elegans visualized by PhDYChol
Finally, to demonstrate the capability of monitoring cholesterol uptake and distribution in vivo, we
used C. elegans as an animal model to study cholesterol uptake and storage. We fed N2 wildtype
C. elegans with PhDY-Chol-labeled E. coli and imaged PhDY-Chol storage in the worms using
our SRL microscope at speed of 40 µs per pixel. PhDY-Chol was found most abundantly in the
intestinal cells inside the wildtype worms (Figure 4.12A). To confirm the uptake of PhDY-Chol
by intestinal cells, we fed ChUP-1 mutant C. elegans, in which dietary cholesterol uptake is
inhibited by ChUP-1 deletion [253], with PhDY-Chol. We did not observe PhDY-Chol inside this
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strain (Figure 4.12B), which indicates that the PhDY tag did not affect the cholesterol uptake
process, which is mediated by ChUP-1.

Then, we tuned the laser to be resonant with C-H vibration for lipid-rich LDs. Unlike CHO cells,
the PhDY-Chol-rich compartments were found to be distinguished from LDs in wildtype worms
(Figure 4.12A). To explore the nature of PhDY-Chol-rich compartments found in our study, we
used hjIs9 worms that contain GFP targeted to lysosome-related organelles (LROs) in intestinal
cells [254]. Dual-modality SRS and TPEF imaging showed that PhDY-Chol is stored in the LROs
(Figure 4.13). We further confirmed the cholesterol storage in intestinal LROs by combining
TPEF imaging of GFP targeted LROs and Raman spectral analysis of hjIs9 worms fed with normal
cholesterol (Figure 4.14). Raman spectrum of LROs showed peaks for sterol C=C bond at 1667
cm-1 and Fermi resonance between asymmetrical CH2 vibrational modes at 2875 cm-1, indicating
the presence of cholesterol in this organelle (Figure 4.14B). Collectively, these results suggest
that, unlike mammalian CHO cells, C. elegans stores cholesterol in LROs, but not in LDs in the
intestine.
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Figure 3.12 SRS imaging of PhDY-Chol visualizes cholesterol uptake in living C. elegans.
SRS images of living (A) wildtype and (B) ChUP-1 deleted C. elegans fed with PhDY-Chol (500
µM) for 3 days. Arrows indicate PhDY-rich particles in the intestine. Image acquisition
speed: 40 µs per pixel for 400 × 400 pixels. Scale bar: 10 µm.
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Figure 3.13 SRS imaging of PhDY-Chol visualizes compartments of cholesterol storage in live
C. elegans.
TPEF and SRS images of live hjIs9 worm fed with PhDY-Chol (500 µM) for 3 days. Arrows
indicate the PhDY-rich particles in LROs. Image acquisition speed: 40 µs per pixel for
400 × 400 pixels. Scale bar: 10 µm.
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Figure 3.14 TPEF imaging and Raman spectral analysis to confirm cholesterol storage in LROs.
(A) TPEF image of hjIs9 worm, which contains GFP targeted to LROs in intestinal cells. Arrow
indicates the point used for Raman spectral analysis. (B) Raman spectrum of GFP
surrounded LROs acquired on the same TPEF microscope. The bands for sterol C=C, and
Fermi resonance between asymmetrical CH2 vibrational modes are indicated by black
arrow. Spectrum acquisition time: 10 s.
Discussion
In this study, we have developed a series of tagged cholesterols based on quantum chemistry
calculations and chemical synthesis. By using PhDY to replace the aliphatic chain in cholesterol,
we produced a cholesterol analog, PhDY-Chol, with a Raman signal that is two orders of
magnitude stronger than the C=O group. By SRS imaging of living CHO cells, PhDY-Chol was
found to be incorporated into the membrane, and converted to PhDY-CE for storage in LDs. With
this cholesterol analog, we experimentally validated that after ACAT inhibition, cholesterol partly
accumulates in lysosomes. In living NPC1-deleted CHO cells, PhDY-Chol selectively represented
lysosomal accumulation of cholesterol in untreated cells, and esterification and relocation to LDs
after HPβCD treatment.

Essential parameters of a valid Raman tag include its amplitude of Raman scattering cross section,
cytotoxicity, and biocompatibility. Although the C-D bond can be used to replace C-H bonds
without changing the structures of the molecules, it gives relatively weak Raman intensities.
Raman signal from alkyne bond is stronger than that from C-D bond by one order of magnitude
[185], and detection at hundreds of micromolar of alkyne-containing molecules by SRS
microscopy was reported [186, 187]. It should be noted that terminal alkyne is known to react with
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the cysteine residues in proteins [255], which might induce cytotoxicity at micromolar
concentrations. In our study, through rational design and synthesis of a PhDY tag, we increased
the Raman scattering cross section by 15 times compared to the alkyne group, and 88 times
compared to the endogenous C=O group. This enhancement is a result of conjugation of electrons among the two CC bonds and the phenyl group. As a result, we have been able to detect
~30 µM of PhDY-Chol molecules (~1,800 molecules at excitation volume), and demonstrated SRS
imaging of PhDY-Chol in single membrane at speed of 6 µs per pixel, and a real-time movie of
PhDY-Chol containing LDs. Importantly, this design also shielded the activity of terminal alkyne
and significantly reduced cytotoxicity. Moreover, PhDY-Chol structurally mimics cholesterol,
using the same physiological process for cholesterol transport and metabolism inside cells. Cell
membrane morphology did not alter when PhDY-Chol was supplemented at high concentrations
when compared to the cells supplemented with the same concentrations of cholesterol (Figure 4.5).
Moreover, the fluorescent property of pyrenedecanoic acid, a membrane fluidity indicator [256],
did not change after CHO cells were treated with 50 µM of PhDY-Chol or 50 µM of cholesterol
for 16 h. These evaluations suggest that the membrane property of the cells was not significantly
affected by addition of PhDY-Chol or cholesterol under our experimental conditions. We note that
using the same strategy, other Raman tag molecules can be designed for sensitive and
biocompatible probing of biomolecules in living cells.

The potential value of a Raman tag is also related to the detection sensitivity of SRS microscopy.
One limitation comes from the cross-phase modulation, which produces a background that reduces
the contrast for the tag molecules. Although broadband femtosecond lasers provide high peak
intensity to enhance the SRS signal [141], they also increase the amplitude of the cross-phase
modulation. As shown in our study, this background can be reduced by 3 times using spectral
focusing [151]. The spectral focusing approach also increases the spectral selectivity, reduces the
photodamage, and provides opportunities to conduct hyperspectral SRS imaging [149].

In this study, we compared BODIPY-cholesterol [120] and PhDY-Chol. Our results show that
PhDY-Chol is stored in LDs via esterification which can be blocked by ACAT inhibition. In
contrast, BODIPY-cholesterol labels LDs even after ACAT inhibition. This result may be due to
the strong hydrophobic interaction of BODIPY with LDs, and is consistent with previous studies
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showing that BODIPY-cholesterol is hardly esterified by ACAT inside the cells [120]. These
results demonstrate that PhDY-Chol, but not BODIPY-cholesterol, reflects the intracellular
behavior of free cholesterol. We also showed that PhDY-Chol reflects the location of the
cholesterol in real-time, unlike filipin staining, which requires fixation. Lastly, SRS microscopy
utilizes chemical-bond vibrational signals for visualization. Thus, unlike fluorophores, the PhDY
tag does not undergo photo-bleaching (Figure 4.12), in contrast to BODIPY-cholesterol and DHE
[112] which is known to have a rapid photo-bleaching rate. Combining these unique properties,
PhDY-Chol allows quantitative imaging of intracellular cholesterol, and repetitive observation of
the same sample before and after treatment.

Figure 3.15 The photostability of PhDY-Chol and the photo-bleaching of BODIPY-Chol.
The SRS images of 50 mM PhDY-Chol solution and TPEF images of 50 mM BODIPY-Chol
solution were acquired continuously for 150 s (one acquisition every 30 s). No significant
change of the SRS signal was observed for PhDY-Chol, and a rapid photo-bleaching was
observed for BODIPY-Chol.
Our work opens new opportunities for mechanistic study of the NP-C disease, a fatal
neurodegenerative disease that shows extensive lysosomal accumulation of cholesterol. Early
detection methods and treatment strategies of this disease are still under development [72]. The
involvement of lysosomal cholesterol accumulation to the neurodegeneration is still unclear [73].
Our in vitro study shows the cholesterol trafficking and metabolism in a cellular model. This can
be extended to in vivo studies using suitable mouse models to understand the progression of the
disease and impact of potential therapeutic strategies, especially in central nervous system.

C. elegans is an important model for genetic and chemical screening in many diseases [257]. It has
been proposed that the intracellular sterol trafficking pathway might be conserved in nematodes
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[258], making it a good model for exploring the genetics of fat storage and lipid metabolism [259].
However, lipid storage in C. elegans has been a debate because of limitations and controversies of
the visualization tool for lipids [176, 177], especially cholesterol. Filipin labeling causes sterol
extraction and some tissues were not accessible with staining [119, 260]. Imaging fluorescent
cholesterol in C. elegans is a challenge due to strong and spectrally overlapping autofluorescence
from the worm [118]. Using label-free CARS microscopy, fat storage compartments in C. elegans
were studied [167, 261]. However, single color CARS microscopy based on the signal from C-H
stretch vibrations cannot tell the compositions of the LDs, and so far it is not clear where the
cholesterol is stored inside the worms. By combination of chemical synthesis of PhDY-Chol and
real-time SRS imaging, we found evidences suggesting the cholesterol storage in LROs. Labelfree Raman spectral analysis was performed to validate the finding. Sterol uptake and transport in
worms are still poorly understood [253], and SRS imaging of PhDY-Chol opens an avenue to
directly assess cholesterol uptake and transport for genome-wide RNA interference screening of
cholesterol transport and storage genes in this animal model. Finally, our work also opens new
opportunities to study cholesterol trafficking and metabolism in other animal models such as
zebrafish and mice.
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4. OUTLOOK

Cholesterol metabolism in cancer
Our study identified CE as a metabolic marker of metastatic PCa, and demonstrated therapeutic
potential of targeting cholesterol esterification to suppress development and growth of metastatic
cancer. Our next step is to validate the correlation between CE accumulation in PCa patient tissues
and the clinical outcomes. At the same time, we will compare the therapeutic efficacy of targeting
cholesterol esterification with the current treatment approaches, e.g. docetaxel or abiraterone, in
preclinical animal models of PCa. It is our expectation that we will provide strong evidence to
support the potential of using cholesterol esterification as a therapeutic target for metastatic PCa.
Notably, avasimibe is a FDA-approved drug for atherosclerosis, which failed due to the lack of
effectiveness. Our study re-purposed the existing drug to treat metastatic PCa, which potentially
saves a lot of cost and risks of drug development. Lastly, the mechanistic study shown in Chapter
2 will contribute to a deeper understanding of altered cholesterol homeostasis in prostate cancer,
and provide a link between abnormal lipid metabolism and oncogenic pathway during cancer
metastasis. Together, these results will serve as a foundation for moving into clinical studies.

Visualizing cholesterol dynamics
We have developed PhDY-Chol and demonstrated its application in studying cholesterol
trafficking in the NP-C disease model and in C. elegans. This study opens new opportunities in
several directions. First, visualizing cholesterol dynamics in living cells and organisms would
enable the discovery of the mechanism of cholesterol trafficking and regulation of cholesterol
metabolism. There are still many processes in intracellular cholesterol transport that are unknown
due to difficulties in monitoring the fate of cholesterol in cells. We expect that SRS imaging of
PhDY-Chol will serve as a novel platform to study the physiological functions of various
cholesterol-binding proteins and to discover novel cholesterol transport mechanisms. New
regulators of cholesterol homeostasis and trafficking can be further identified by combining with
genome-wide RNA interference screening. Second, PhDY-Chol can be applied to study the
functional roles abnormal cholesterol transport and metabolism in other diseases, such as
atherosclerosis and Tangier disease, to facilitate the development of new therapeutic approaches.
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Third, high-throughput screening of cellular response to drugs for treating cholesterol-related
diseases, such as NP-C disease or cancer, would allow discovery of new therapeutic targets and
mechanisms. SRS imaging of PhDY-Chol allows real-time assessment of cholesterol trafficking
and metabolism, which can provide faster readouts after the treatment. Lastly, by incorporating
PhDY tag, dynamics of other essential sterols, such as oxysterols, can be visualized in living cells.
In summary, future studies on cholesterol trafficking and metabolism using SRS imaging of
PhDY-Chol will contribute to more complete understanding of cholesterol dynamics, which is an
indispensable lipid in mammalian cells.

Imaging small molecules using Raman tag
Using the strategy described in Chapter 3, other Raman tag molecules can be designed for imaging
small molecules in living cells. Most of fluorescent labeling introduce bulky fluorophores or
fluorescent proteins to molecules of interest, which sometimes interfere with its functions.
Designing and incorporation of a smaller labeling group, such as Raman tag, is especially
advantageous to labeling of small molecules for minimal perturbation. We expect that this
technique would enable characterization of the distribution of small metabolites or proteins with
its physiological functions. It would be also important to develop novel Raman tags that can be
used to measure in vivo activities of target molecules such as enzymes or receptors. In summary,
Raman spectroscopic imaging is a valuable tool in studying chemistry in situ inside living cells and
organisms.
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